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Drug discovery is an expensive and time-consuming process which requires large 
amount of financial investment. Efforts in bioinformatics and cheminformatics are 
extensively explored to increase the efficiency and reduce costs of drug discovery and 
development. Bioinformatics tools such as database and computational methods such 
as machine learning method based virtual screening (VS) have been developed for 
searching novel lead compounds. 
 
Database development is a promising approach which can accelerate drug discovery 
by systematically managing and providing medicinal chemicals and biomolecules 
information with a web accessible interface. This information is a useful resource for 
further drug discovery application besides a data storing pool. VS is known to 
contribute to discovery of hits and lead compounds and VS has been investigated and 
explored intensively. Various tools and applications have been developed according 
to VS. However, there are many issues of many conventional VS tools including 
insufficiency of compound diversity coverage, slow screening speed of large 
compound libraries and high false positive rate. It is demanded to overcome these 
problems and it would be very useful to develop application of VS tools to discover 
novel compounds by screening large compound libraries rapidly at good yields and 
low false-hit rates. 
 IX 
 
In this work, several computational approaches for facilitating disease detection and 
drug discovery are presented. MicrobPad MD: Microbial pathogen diagnostic 
methods database is built to provide comprehensive information about the molecular 
detection for pathogens. It may help accurate, sensitive and low-cost detection of 
medical pathogens and diagnosis of disease. The updated TTD is expected to be a 
useful resource in complement to other related databases by providing comprehensive 
information about the primary targets and drug of the approved, clinical trial, and 
experimental drugs. These database lead to a better understanding of the disease and 
benefit for drug discovery. 
 
Src promotes tumour invasion and metastasis, and facilitates VEGF-mediated 
angiogenesis and survival in endothelial cells. Both Src and VEGFR-2 are very 
important for disease, particularly cancers. To facilitate drug discovery by saving time 
and cost in developing novel lead, the machine learning methods are used to build 
screening models for Src and VEGFR-2 inhibitors. It is shown that SVM based VS 
tools work efficiently in the discovery of Src, VEGFR-2 inhibitors and other active 
compounds at low false-hit rates. The virtual hits of models have been tested 
experimentally to further verify the models. These projects facilitate drug discovery 
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Chapter 1 Introduction 
Disease detection and drug discovery is typically a costly and lengthy process which 
takes more than 10 years to develop a successful drug from initial design to market. 
Although a log of efforts have been made for drug discovery, the successful drugs did 
not increase significantly over the past few decades. Bioinformatics and 
cheminformatics tools are explored to make drug research and development more 
efficient and effective. To help achieve this purpose, this work on "Development of 
Database and Computational Methods for Disease Detection and Drug Discovery" is 
conducted as one of the strategies illustrated in this chapter. The thesis contains 
database development of disease detection and therapeutic targets as well as 
discovery of potential drug lead by silico virtual screening. This introduction chapter 
includes: (1) conventional and molecular detection methods of pathogen; (2) 
bioinformatics and cheminformatics in drug discovery; (3) database development; (4) 
virtual screening of drug discovery; (5) objectives and outlines. 
 
1.1 Overview of pathogen detection  
1.1.1 Application areas requiring pathogen detection. 
The detection of pathogens is the most important procedure for the identification and 




areas especially in clinical diagnostics, environment quality control and food industry 
where failure to detect pathogens. The pathogen detection has become the critical part 
in many research areas and application areas including pathology research, disease 
diagnosis, biodefense, food and water safety and epidemic prevention. Three 
application areas account for over two thirds of all research in the field of pathogen 
detection including food industry, water and environment quality control and clinical 
diagnosis [1-3]. Particularly in European Union, about 275 million pathogen detection 
of food were conducted in 2011 and this number in 2016 will to get to 350 million [4].  
 
1.1.2 Brief introduction to pathogens induced infectious diseases 
A biological agent that cause diseases to its host is known as pathogen. Pathogens are 
most often used to refer to numerous infectious microorganisms such as bacteria, 
viruses, fungi and parasites which infect unicellular or multicellular organisms 
including human, animals and plants by disrupting the normal physiological function 
[5]. Pathogenic diseases is a term used for the diseases clinically caused by pathogen. 
Usually there are four kinds of pathogens including bacteria, viruses, fungi and 
parasites [5, 6]. Brief Description of four categories of pathogen together with the 






Table 1-1 Four categories of pathogen inducing infectious human disease. Their infection are briefly 






Description of infection  Examples of pathogen Associated diseases 
Bacteria 1-5 µm 
Inhibit immune system and 
released edotoxins, extoxins and 
toxic factors which will block 
host protein synthesis, make 
cell deficient or cause 
inflammatory reaction. 
Escherichia Coli Food poisoning 
Chlamydia pneumoniae [7] Atherosclerosis 
Helicobacter pylori [8] Psoriasis 








Infection and the severe level of 
disease symptoms are relied on 
the virus virulence factors. 
Receptor typically endocytosed 
protein are often required on 
host cells for virus binding. 
Virus virulence factors can 
block MHCI processing for host 
immune system dysfunction. 
Human immunodeficiency 
virus (HIV) [12] 
AIDS 
Dengue virus [13] Dengue fever 
SARS coronavirus [14] 
Severe acute respiratory 
syndrome (SARS) 
Ebola virus [15] Ebola hemorrhagic fever 
Coxsackie A virus, 
Enterovirus 71 (EV-71) [16] 
Hand, foot and mouth 
disease (HFMD) 





Fungi diseases are induced 
through host barriers 
penetration or immunological 
debilitation by fungi. Fungi 
infect host through three ways: 
iatrogenicity, trauma or 
inhalation [18]. The common 
fungal diseases include 
respiratory fungal allergy, 
immune reconstitution 
inflammatory syndrome, skin 
diseases, mucosal infections and 
Blastomyces dermatitidis [19] Blastomycosis 
Candida albicans [20] Thrush 





Although medical advances have been made to protect human from pathogen 
infection, pathogens still threaten human life and difficult for treatment since the 
variation of the pathogens, particularly viruses, is significant fast. Over the decades, 
more serious pathogen diseases have been induced by viruses such as human 
immunodeficiency virus (HIV), hepatitis B, meningococcal disease [26] and some 
cancer such bladder cancer [27] and cervical cancer [28]. The pathogenic diseases are 
extremely harmful for human health and life quality. Table 1-2 shows the top 10 
leading cause of death worldwide in 2008 reported by WHO fact sheet [29]. Four 
eosinophilia-driven 
hypersensitivity diseases. Fungi 
can also induce opportunistic 






Traditionally, there are more 
than one host within lifestages 
of pararsite. Parasite can be 
divided into four types: 
roundworms, tapeworms, flukes 
and single celled protozoa. 
Some parsites can cause 
diseases by toxins, others 
directly cause diseases. Parasitic 
infection can be caused by 
contamination of soil, water, 
food, pet and insect. The 
parasite infection is typically 
chronic and immunology 
defection. 
Entameba histolytica [22] Amoebiasis 
Ascaris lumbricoides [23] Ascariasis 
Plasmodium malariae, 
Plasmodium ovale [24] 
Malaria 




pathogenic diseases involved in the top 10 causes of death worldwide and the total 
proportion of all the death is up to 15.90%.  
Table 1-2 The top 10 leading cause of death worldwide in 2008 reported by WHO fact sheet. 
World Deaths in millions % of deaths 
Ischaemic heart disease 7.25 12.80 
Stroke and other cerebrovascular disease 6.15 10.80 
Lower respiratory infections 3.46 6.10 
Chronic obstructive pulmonary disease 3.28 5.80 
Diarrhoeal diseases 2.46 4.30 
HIV/AIDS 1.78 3.10 
Trachea, bronchus, lung cancers 1.39 2.40 
Tuberculosis 1.34 2.40 
Diabetes mellitus 1.26 2.20 
Road traffic accidents 1.21 2.10 
 
Although the many effort have been made to diagnosis and treatment of pathogenic 
diseases, challenges exist in accurately identifying pathogens rapidly. According to 
the world health statistics report [30], pathogenic diseases mortality rate is still 
significant as shown in Table 1-3. Some pathogenic diseases e.g. H5N1 influenza 
[31] induce high mortality rate due to mutations. Some diseases e.g. poliomyelitis 
[32] cause very bad consequence even with low mortality rate. Therefore, early 
detection of pathogens to identify the pathogenic sources is extremely important for 
fast disease diagnosis, proper treatment and pathogenesis processes research. It is 





Table 1-3 Three pathogenic diseases mortality rate in 2013. 
WHO region Pathogenic diseases mortality rate (per 100 000 population) 
HIV/AIDS Malaria Tuberculosis among 
HIV-negative people 
2001 2011 2010 2000 2011 
African Region 219 139 72 37 26 
Region of the Americas 12 9 0.2 3.6 2.2 
South-East Asia Region 14 12 2.4 43 26 
European Region 5 11 NA 8 5 
Eastern Mediterranean 
Region 
4.8 7.7 3.5 29 16 
Western Pacific Region 2.4 4.4 0.2 12 6.9 
1.1.3 Conventional pathogen detection methods 
Traditionally, microbial morphology and growth variables are the predominant 
characteristics using for microorganisms identification and differentiation through 
morphologic features, growth variables, and biochemical utilization of organic 
substrates [37]. In addition to phenotypic approaches based on various medium, other 
methods have been developed and used for pathogen detection over decades. For 




smear analysis and manually or semi-automated biochemical testing for 
characterization of pathogens have been widely applied. 
 
However, there are significant drawbacks existing in these conventional methods 
because they highly depend on traditional microbiology characteristics and chemical 
profiles monitoring approaches which are time-consuming, high cost, low sensitivity, 
high manpower cost and require labile natural products. Due to the cultivation time of 
microorganisms, high expense, false positives and causative agent, it is difficult to 
conduct high-throughput screening for environmental and clinical samples. Moreover, 
these techniques that are routinely established for pathogen identification but do not 
directly identify virulence factors [38]. These methods cannot provide important 
information of the identified pathogens about the potential pathogenesis and virulence 
factors for further research. In summary, to overcome the problems of conventional 
identification methods, more reliable, rapid and accurate tools for pathogen 
determination have been developed. 
 
1.1.4 Molecular pathogen detection methods 
There are numerous molecular techniques have developed to detect pathogens with 
the advantage of speed along with the relative simplicity, specific and sensitive 




molecular detection technology. It plays a key role when great efforts made to 
development of pathogen detection. Nucleic acid based methods rely on the premise 
that unique DNA or RNA sequences marker of an organism is specific and different 
from other species. The unique sequence can be used as a detection target of a 
pathogen. The nucleic acid based molecular methods include several kinds of nucleic 
acid amplification techniques such as polymerase chain reaction (PCR), reverse 
transcriptase polymerase chain reaction (RT-PCR) and quantitative PCR (Q-PCR), 
molecular beacon technology [40], fluorescent in situ hybridization (FISH) [41], 
microarray based strategies. Among these molecular detection methods, 
microarray-based detection is considered as the technique of high sensitivity, 
specificity and throughput because it can integrate nucleic acid amplification and high 
throughput screening technique  Nucleic acid probes using in microarray technique 
are able to identify pathogen organisms at, above, and below the species level [37]. 
However, microarray based detections cost a lot and require plenty of PCR reactions  
which are complex for arrangement. These disadvantages of microarray application 
have severely impeded the utilization and further development of this technique. 
 
Molecular detection methods are much safer using in laboratory than conventional 
methods. Some pathogens such as Mycobacterium tuberculosis, Influenza A virus and  




43]. These organisms have severe risks for laboratory worker and may contribute to 
severe diseases or mortality. 
1.2 Bioinformatics and cheminformatics in drug discovery 
The combination of random screening and rational drug design have played an 
important role in drug discovery [44]. The traditional drug discovery process 
comprise seven basic steps including disease selection, target selection, lead 
compound identification, lead optimization, preclinical trial evaluation, clinical trials 
and drug manufacturing [45]. Drug discovery process costs typically 10-17 years and 
$800 million totally, but success rate is still less than 10%. Definitely, it is a 
time-consuming, expensive and low success rate procedure [46]. Target, efficacy and 
safety are three major problems of current drug discovery strategy. Current drugs 
design aims at a few know targets, but many targets for existing diseases and new 
diseases are still unknown. Novel targets are demanded to be investigated to treat new 
disease or overcome drug resistances problems. Some drug candidates may lose 
efficacy or cause safety issues such as severe side effects during the clinical trials 
phage. 
New techniques have been utilized to drug discovery to make it more effective and 
efficient especially in early stage of drug discovery such as target selection, lead 




biology and genomics for comprehensive understanding disease mechanism and 
therapeutic intervention, new techniques including microarray, genomic DNA 
sequencing, RNA-seq, Chip-seq, and high throughput screening have been applied 
and shown great potential for solving current problems. For instance, genomic DNA 
sequencing and next generation sequencing combining bioinformatics may help 
identify up to 10,000 new molecular targets [47]. On the chemistry side, HTS and 
cheminformatics may help discover new leads from large compound library. 
Bioinformatics, an interdisciplinary of biology, mathematics and computer science, 
mostly refers to informatics processes in biotic systems [48]. Bioinformatics can 
develop computational methods and tools to obtain and analysis data as well as 
generate biological knowledge [48]. Cheminformatics aims to use computer and 
informational techniques to solve a serious of chemistry problems [49, 50]. 
 
Bioinformatics and cheminformatics tools are developed which are able to congregate 
all the required information regarding potential targets like nucleotide and protein 
sequencing, homologue mapping [51, 52], function prediction [53, 54], pathway 
information [55], structural information [56] and disease associations [57], chemistry 
information. The availability of that information can help pharmaceutical companies 





1.3 Introduction of bioinformatics and cheminformatics database 
development 
Since the biological and chemistry data increase rapidly due to the new technology 
such as HTS and nucleotide sequencing, it is necessary to collect, store and manage 
data effectively to assist research on disease mechanisms and drug candidates. 
However, some data may lack of organization and standard format from different 
resource. Further process of validation and analysis are needed for the data to extract 
useful information. Implementation of tools is also required to provide an easy and 
powerful way for data access. Database is such a technique can meet these 
requirements by providing latest information and data that related to disease 
mechanism studies, pharmaceutical research and drug development. They provide 
interdisciplinary data of different areas such as biological information, chemistry 
information, bioinformatics and chemoinformatics data, system model of pathway, 
bimolecular interaction data and so on. Databases store data in various formats such 
as relational database tables, XML files, YML files, flat files, protein structure 3D 
object files. 
 
Databases have been developed over decades. There are many public bioinformatics 
cheminformatics databases available which are listed in Table 1-4 and Table 1-5. In 




detection and therapeutic targets and drugs. Owing to the effort of target discovery, 
hundreds of success targets and more than 1000 research targets have been identified 
[58-61]. There are several well known target and drug databases available such as 
SuperTarget [62], BindingDB and DrugBank. 
 
Table 1-4 Popular bioinformatics databases. 
Database Description Web link 
National Center for 
Biotechnology Information 
(NCBI) 
Biomedical and genomic 
resource funded by U.S. 
government. 
http://www.ncbi.nlm.nih.gov/ 
EMBL-EBI Integrated bioinformatics 
research and services  
http://www.ebi.ac.uk/services 
NCBI GenBank Publicly available annotated 
DNA sequences 
http://www.ncbi.nlm.nih.gov/genbank/ 
DNA Data Bank of Japan 
(DDBJ) 
Sole nucleotide sequence data 







NCBI Genome Sequence and map data of the 
whole genomes 
http://www.ncbi.nlm.nih.gov/genome/ 
Genomes OnLine Database 
(GOLD) 




TIGR  Plant Transcript Assemblies http://plantta.jcvi.org/ 




Resource (CMR)  




Microbial Genome Database 
for Comparative Analysis 
(MBGD) 
Comparative analysis of 
microbial genomes 
http://mbgd.genome.ad.jp/ 
Clusters of Orthologous 
Groups of proteins (COG) 
Comparative protein 
sequences based on complete 
genomes 
http://www.ncbi.nlm.nih.gov/COG/ 
Mitomap human mitochondrial genome http://www.mitomap.org/MITOMAP 





ally annotated and reviewed; 
UniProtKB/TrEMBL: 
automatically annotated and 
not reviewed 
BRENDA Collection of enzyme data http://www.brenda-enzymes.org/ 




Pfam Collection of protein families http://pfam.sanger.ac.uk/ 




SUPFAM Homologous protein domain 
families 
http://supfam.mbu.iisc.ernet.in/ 
ExPASy - PROSITE Patterns and profiles of protein 






classification of PDB protein 
structures 
http://www.cathdb.info/ 
PRINTS Protein fingerprints http://www.bioinf.man.ac.uk/dbbrowse
r/PRINTS/index.php 
SCOP: Structural 
Classification of Proteins 
Detailed structural and 
evolutionary relationships of 
PDB protein 
http://scop.mrc-lmb.cam.ac.uk/scop/ 
Protein Data Bank Structures of proteins, nucleic 
acids, and Complex  
http://www.rcsb.org/pdb/home/home.d
o 
MMDB Protein structure at NCBI http://www.ncbi.nlm.nih.gov/Structure/
MMDB/mmdb.shtml 
BIND The Biomolecular 
Interaction Network 
Database 
Molecular interactions http://bond.unleashedinformatics.com/ 
Database of Interacting 









KEGG  Collection and manually 





Signal transduction and 





BioCarta Dynamic graphical pathway 
map 
http://www.biocarta.com/ 





Biochemical Pathways http://web.expasy.org/pathways/ 
 
 
Table 1-5 Popular chemical databases 
Database Description Web link 
BindingDB Binding affinities of proteins and 
protein ligand 
http://www.bindingdb.org/bind/index.jsp 




PubChem  Information on the biological active 
molecules 
http://pubchem.ncbi.nlm.nih.gov/ 
ZINC  Commercially-available compounds 
for virtual screening 
http://zinc.docking.org/  
ChEMBL Bioactive molecules http://www.ebi.ac.uk/chembl/  
DrugBank  Drug data with drug target http://www.drugbank.ca/  
eMolecules  Chemical molecules commercial 
available 
http://www.emolecules.com/  
WOMBAT Chemogenomics with bioactivity 
annotations 
http://www.sunsetmolecular.com 
4SC Targeted small molecule drugs www.4sc.de 
chemspider Over 28 million free chemical structure http://www.chemspider.com/ 
NIST Chemistry 
WebBook 
Thermochemical, thermophysical, and 
ion energetics properties 
http://webbook.nist.gov/chemistry/ 






46 million unique structures http://cholla.chemnavigator.com/cgi-bin/loo
kup/search 
ChemDB Nearly 5 million small molecules http://cdb.ics.uci.edu/CHEM/ 
AffinDB Affinity data of PDB protein-ligand http://pc1664.pharmazie.uni-marburg.de/aff
inity/index.php 
ChemBank Small molecules library with over 





ChemIDplus Free 350000 chemical compounds http://chem.sis.nlm.nih.gov/chemidplus/ 




Manufacturer of amino acids, 
chemicals and reagents 
https://www.advancedchemtech.com/ 
Asinex Libraries of medicinal chemistry, 
including biodesign, synergy, 




Combinatorial building blocks, 
organics and chemicals 
http://www.combi-blocks.com 
ComGenex Freely accessible chemicals catalog http://www.rdchemicals.com/index.html 
EMC 
microcolection  
Organic chemical and Biochemicals  http://www.microcollections.de/ 
InterBioScreen 










Biocompatible compounds and pure 
natural products 
http://www.msdiscovery.com 
Polyphor Innovative pharmaceutical compound http://www.polyphor.com 
Sigma-Aldrich  Drug-like compounds 
http://www.sigmaaldrich.com/chemistry/dru
g-discovery.html 
Specs.net Over 240,000 true novel compounds 
http://www.specs.net/snpage.php?snpageid=
home 
TimeTec Over 1,000,000 Chemical Structure http://www.timtec.net/ 
Tripos 




Over 900,000 diverse compounds and 
14,000 chemical building blocks 
http://www.chembridge.com/index.php 
ChemDiv Drug discovery compounds http://eu.chemdiv.com/ 
 
1.4 Overview of virtual screening in drug discovery 
High throughput screening (HTS) known as a fast test large amount of chemicals tool 
has been used extensively in pharmaceutical industry. However, HTS has problems of 




HTS process still costs approximately US $75,000.[63]. The cost will get much higher 
if expensive assay is integrated. Moreover, the entire chemical space is too huge to be 
covered by natural and synthesized compounds which only occupy limited proportion 
of the chemical space [64, 65]. Even if only drug-like compounds are considered, 
chemical space of drug-like compounds is still magnitude larger than that of 
pharmaceutical industry screening collection [66]. Considering these drawbacks, it is 
necessary to explore technologies to complement HTS assay and synthesis. 
 
Virtual screening (VS) is a computational technique used in drug discovery research. 
It involves rapid in silico assessment of large libraries of chemical structures in order 
to identify those structures that are most likely to bind to a drug target, typically a 
protein receptor or enzyme [67, 68]. VS has been used to describe a process of 
computationally analyzing large compound collections in order to prioritize 
compounds for synthesis or assay. During the last decade, a broad range of 
computational techniques have been applied to search for novel bioactive compounds 
for many targets. VS has been extensively explored for facilitating lead discovery 
[69-72], identifying agents of desirable pharmacokinetic and toxicological properties 
[73, 74] and other areas. There are two broad categories of screening techniques: 
structure-based virtual screening (SBVS) and ligand-based virtual screening (LBVS) 




followed by the estimation of the probability of the high affinity binding between 
them calculated by a scoring function. LBVS methods, such as pharmacophore 
methods and chemical similarity analysis methods, require the ligand structure 
information, they focus on discovery the new drug hits by analyzing the physical and 
chemical similarities of known compound pools by computational means. Figure 1-1 






Figure 1-1 SBVS and LBVS for drug discovery procedure (adopted from Ref [76]). SBVS is shown on 
the left and LBVS is shown on the right. 
 
Structure-based virtual screening (SBVS) starts with a 3-D structure of a target 
protein and a database of the 3-D structures of ligands as the screening pool. It is 
usually applied when the 3D structure of a protein target, derived either from 




available. The SBVS procedure consists of docking and scoring. Docking is most 
straightforward VS method and it is preferred by the chemists. The docking 
algorithms [77, 78] are designed to predict the ligand conformation and orientation 
within the targeted active site of the target. The scoring methods are empirically or 
semi-empirically derived to attempt [79] to estimate the binding tightness of the 
ligand and the protein in bound complexes. Docking and scoring algorithms are 
combined to detect the compounds with higher affinity against a target by predicting 
their binding mode (by docking) and affinity (by scoring), and retrieving those with 
the highest scores. To date, more than 60 docking programs and 30 scoring functions 
have been reported [80, 81]. The major drawback with SBVS is the unavailability of 
appropriate scoring functions to differentiate between correct and incorrect poses of 
bound ligands and identifying false negative and positive hits. Some of the key 
challenges encountered by SBVS include the appropriate treatment of ionization,  
tautomerization of ligand and protein residues, target/ligand ﬂexibility, choice of force 
ﬁelds, solvation effects, dielectric constants, exploration of multiple binding modes 
and, most importantly, the approximations in the scoring functions that lead to 
false-positives and miss true-hits. Moreover, most docking algorithms and scoring 
functions are tuned towards high throughput, which requires a compromise between 
the speed and accuracy of binding mode and energy prediction. The hit enrichment is 




ranked VS hit list compared with the average fraction of active compounds in the 
search space. The performance of a docking program is difficult to evaluate in 
advance, and depends on the nature and quality of the target structure [80-82]. Despite 
all optimization efforts, the available scoring functions do not provide reliable 
estimates of free binding energies, and are not able to rank-order compounds 
according to affinity [81, 83]. The published comparisons of docking programs have 
been critically reviewed [84-86].  
 
As compared with structure-based methods, LBVS methods including pharmacophore 
methods and chemical similarity analysis methods have shown better performance in 
terms of speed, yield and enrichment factor. Hit rate is defined as the relation between 
the number of true hits found in the hit list respect to the total number of compounds 
in the hit list; and the enrichment factor (EF) is the hit rate divided by the total 
number of hits in the full database relative to the total number of compounds in the 
database. To improve the coverage, performance and speed of VS tools, machine 
learning (ML) methods, including SVM, neural network and etc, have been used for 
developing LBVS tools [87-94] to complement or to be combined with SBVS [69, 
95-106] and other LBVS [70, 107-110] tools. ML methods have been used as part of 
the efforts to overcome several problems that have impeded progress in more 




the vastness and sparse nature of chemical space needs to be searched, limited 
availability of target structures (only 15% of known proteins have known 3D 
structures), complexity and flexibility of target structures, and difficulties in 
computing binding affinity and solvation effects. ML methods have been explored for 
developing such alternative VS tools [87-89] because of their high speed [112] and 
capability for covering highly diverse spectrum of compounds [113]. Han et al [114] 
did a comparative study for reported performance of different VS methods in 
screening large libraries of compounds as shown in Table 1-6. ML methods show 
good potential for a better performance at VS of extremely large libraries with over 
1M compounds. The reported yield, hit-rate and enrichment factor of ML tools are in 
the range of 55%~81%, 0.2%~0.7% and 110~795 respectively [88, 91, 93], compared 
to those of 62%~95%, 0.65%~35% and 20~1,200 by SBVS tools [98, 99]. Moreover, 
he also developed a new putative negative generation method in which negatives were 
generated from 3M PubChem compounds. With this method he significantly 
improved yield, hit-rate and enrichment factor to 52.4%~78.0%, 4.7%~73.8%, and 
214~10,543 respectively in screening libraries of over 1 million compounds. For 
SBVS methods, approaches of using additional filters are often required in order to 
further minimize the false positives. One approach is the selection of top-ranked hits, 
which has been extensively used in LBVS [88, 89, 93, 94, 115, 116] and SBVS [98, 




unpromising hits in pre-screening stage by using such filters as Lipinski’s rule of five 
[119] [99], and recognition of pharmacophore [101] and specific chemical groups or 
interaction patterns [98, 100, 104, 120]. The last one is the combination of LBVS and 
SBVS methods. All these approaches take quite some time. However, they are not 





Table 1-6 Comparison of the reported performance of different VS methods in screening large libraries of compounds (adopted from Han et al[114]). 
Type of VS method 







Compounds screened Virtual hits selected by 
VS method 




























libraries ( ≥1M) 
Docking + 
pre-screening 
filter (2) [98, 99] 
1M~2M 355~63
0 













375~4.5K 0.28%~3% 5~231 2%~ 30% 
 




libraries ( ≥1M) 
Machine learning 
- SVM (2)[88, 91, 
93] 
2.5M 22~46 0.0009%~ 
0.0018% 









~0.07% 1.7K 1% 26~70 22%~ 55% 1.5%~ 4.1% 22~55 
Machine learning 










– BKD (12)[89, 







5.1K 5% 65~972 14%~ 94% 1.2%~ 18.9% 3~19 
Machine learning 
– LMNB (1)[91, 
93] 
172K 118 0.069% 1.7K 1% 19 16% 1% 15 
Machine learning 







































































380K 30 0.0079% 6917 1.82% 23 76.7% 0.33 41.8 
Ligand-based VS, 
extremely large 






SVM[114] 2.986M 2351 0.076% 8157 0.27% 1833 78.0% 22.5% 296 
SVM[114] 2.986M 225 0.007% 160 0.0054% 118 52.4% 73.8% 10543 
SVM[114] 2.986M 37 0.0012% 299 0.01% 23 62.2% 7.7% 6417 




As it is common for the pharmaceutical industry to screen >1 million compounds per 
high-throughput screening campaign [123]. A small rise in the hit rate will lead to 
hundreds or thousands compounds to test. Improvement in screening performance is 
therefore very significant. We want to further improve SVM based VS as a well 
accepted VS method like docking. Current models were generated by using two-tier 
supervised classification SVM methods [87-89, 91-94, 111]. The inactive compounds 
in these models have been collected from up to a few hundred known inactive 
compounds or/and putative inactive compounds from up to a few dozen biological 
target classes in MDDR database [87-89, 91-94, 111], which may not always be 
sufficient to fully represent inactive compounds in the vast chemical space, thereby 
making it difficult to optimally minimize false hit prediction rate of ML models. Han 
et al[114]  has demonstrated the potential of putative negatives generation method in 
helping to increase the performance of SVM based VS methods. We will carry on the 
study to further improve the method to generate more diverse negatives for training. 
Besides SVM, some other common ML methods include artificial neural network 
(ANN), probabilistic neural network (PNN), k nearest neighbor (kNN), C4.5 decision 
tree (C4.5DT), linear discriminate analysis (LDA) and logistic regression (LR) were 
used.  Some of these methods will be explained in Chapter 2 and attempted for 
comparison. Several types of pharmaceutical agents, including Src kinase inhibitors, 




also evaluated in terms of prediction on novel types structures because it is also one 
goal of VS [75]. 
 
1.5 Objective and outline of this thesis 
The ultimate goal of this thesis is to develop comprehensive databases to facilitate 
disease detection and drug discovery for the disease using computation methods. 
Overall, there are three major objectives for this work: 
1. To develop and update databases with enhanced storage, management, integration 
and provide the customized biological and chemistry information data for pathogen 
detection, disease diagnosis, therapeutic targets and drugs. 
2 To develop SVM based virtual screening method for prediction of potential Src 
and VEGFR-2 inhibitors from large compound libraries and test the model 
experimentally. 
3 To compare the virtual screening performances of several the machine learning 
methods SVM, kNN, PNN and similarity searching in identification of inhibitors. 
 
The complete outline of this thesis is as follows: 
Chapter 1 describes pathogen induced diseases and their detection methods, and 
introduces background of cheminformatics and bioinformatics. Then the introduction 




Chapter 2 shows methods used in this work, including database development method 
and procedure of the application of VS tools. In particular, data collection, theoretical 
backgrounds of machine learning methods, virtual screening model validation and 
performance measurements. 
 
Chapter 3 and Chapter 4 elaborate the development of MicrobPad MD: Microbial 
pathogen diagnostic methods database and update of therapeutic targets database. 
 
Chapter 5 and Chapter 6 are devoted to the application of our SVM based VS 
system for pharmaceutical agents Src and VEGFR-2 inhibitors from large compound 
libraries. In these chapters, SVM based VS system combined with a novel putative 
negative generation method is evaluated as a highly efficient VS tool. The comparison 
between kNN and PNN based VS model are described. 
 
Chapter 7 summarizes major findings and contributions of current work and also 
rationalizes the limitations and suggestions for future studies.  
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Chapter 2 Methodology 
This chapter includes methods of database development and virtual 
screening for drug agents. The database development methods is usually 
consisted of the following four components: (1) database design; (2) data 
collection; (3) data integration and organization; (4) user interface. Methods 
of virtual screening include (1) Datasets collection and quality analysis; (2) 
Molecular descriptors calculation; (3) Machine learning methods; (4) 
Machine learning methods model development and evaluations; 
2.1 Database development 
A database is a well-organized data collection of information and their 
supporting data structures, typically in digital form. It involves the data and 
their supporting data structures. Database development is comprehensive and 
time consuming involving collecting relevant data, designing reasonable 
database scheme, integrating data from various resource, designing database 
interface and implementing database function. 
 
2.1.1 Database model and rational schema design 
A database model is a theoretical foundation of a database and 
fundamentally determines in which manner data can be stored, organized, 
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and manipulated in a database system. There are several different basic ways 
of constructing databases including flat file model, hierarchical model, 
network model, relational model, dimensional model, multi-value model and 
object-oriented model. The relational model has been extensively used in 
biological database development. Relational database comprises multiple 
tables of data, related to each other by primary keys and foreign keys. Each 
table is a collection of records and each record in a table has the same 
attributes. Relational database is the predominant form of database in use 
today, especially in biological research field. In this study, the relational 
model was applied in the database development. After relational model was 
selected, a rational schema is important for the database construction. 
 
A rational schema is designed before the construction of the database to help 
define the scope of the database and focus on relevant problem. Information 
need to be collected to pave the way for the information collection stage. The 
database performance, the ease with which users retrieve information, the 
search engine coding and other database function implementations are 
greatly influenced by the schema design. Therefore, schema design is the 
fundamental step in planning a new database is to identify and design the 
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tables to be included in the database, specify their contents, and define the 
relationships among them. 
 
Use MicroPad MD for an example, as described in Chapter 1, medical 
pathogens of bacterial, fungal, and viral species induce infections, disease 
and sometimes serious medical conditions in the infected hosts. Fast, 
accurate, sensitive and low-cost diagnosis of medical pathogens is important 
and desired for proper treatment and investigation of pathogenesis processes. 
To facilitate the development of diagnostic methods and device, MicrobPad 
MD was designed to provide comprehensive information about diagnostic 
technique, targets, and primers/probes for the known bacterial, fungal and 
viral pathogens. Based on this preliminary architecture, the more details 
schema including several tables and their relationships was built. 
 
2.1.2 Data collection 
Generally, a database is supposed to provide enough domain knowledge 
around a specific subject together with information of related subjects. For 
instance, MicrobPad MD provides integrated molecular diagnostic 
information including molecular diagnostic techniques, targets, 
primers/probes, virulence factors, disease, etc. Data collection of these 
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information can be done by various ways. Data can be captured from 
literature, books, experiments or software output, customized data collected 
programmatically from other databases locally or over the internet, text 
mining by programs, and so on. Literature is typically on unstructured data 
source. Names of the subjects that are stored in different synonymous terms, 
various abbreviations, or totally different expressions, are difficult to be 
recognized by automatic language processing. It is very difficult to invent a 
fully automated literature information extraction system to gather useful 
information from literature efficiently. Manual data collection from literature 
or manual curation of collected data is considered be one of the most feasible 
ways for information data collection. However, it is too time consuming and 
expensive [124]. A number of solutions for this problem are in practice. Data 
curation and annotation can be done in collaboration with other groups or 
providing online facility to edit or submission of data [125]. 
 
In this work, automatic data retrieval methods with manual curation process 
was combined to ensure good quality. It is useful to have program parser to 
filter the data since the amount of biological data is generally very huge. 
Automated text retrieval programs developed in PERL with efficient use of 
regular expression were implemented in retrieving information from 
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literatures that contained the key word related to searching the subject via 
local Medline packages [126]. The useful subject information was selected 
manually and the full literature was referred to facilitate information 
searching. Meanwhile, the detail biological information of subject and 
cross-links were automatically extracted from some general or specific 
biological databases, such NCBI genome, SwissProt and UniProt. Moreover, 
an html parser was also written to parse some html pages with unstructured 
data. The information obtained by the program were extracted and verified 
manually. 
 
2.1.3 Data integration and organization 
Data is still often available in an unstructured manner even when it does 
have a strong internal structure. Data integration is a necessary procedure 
when data from different sources needs to be standardized before 
implementation. The integration of biological and chemical data coming 
from various source sometimes become a big challenge. Improper integration 
can lead to missing of some part of data or even can induce mistakes. The 
correct way of data integration for biological databases can generally be 
divided into two parts: syntactic integration and semantic integration. In 
syntactic integration, data from different sources and of different file formats 
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are standardized to have single file format. In semantic integration, data from 
different databases are formalized to have a relational schema which holds 
relational tables and integrity constraints. For syntactic integration, the 
standardized file format to which other data should be converted is generally 
XML (extensive markup languages). The structure of XML is such that it 
can hold data of various types such as simple plain table, tree like data, 
relational tables and web pages. This easy conversion capability of XML 
makes it extremely useful format for exchange of data over web and database 
software. In this work, the powerful feature of XML has been utilized for 
various purposes e.g. collection of PubMed extracts for the medical pathogen 
as keywords using NCBI E-utilities. On the other hand, semantic data 
integration gives flexibility to mix complex biological data in semi structured 
way when it is difficult to standardize a part of data to the convention of 
unified single file format. In addition, data can be integrated manually. 
Information curation process is time consuming and tedious but sometimes it 
becomes indispensible to ensure data achieves high quality. Manual data 
integration is also achieved through scripting languages like PERL or Python 
which are handy to use yet very powerful. Scripts can help manipulate 
database tables by integrating plain unformatted text taken from literature or 
web page. Relied on the power of programming languages, major public 
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databases hosted by NCBI and EMBL provide data access service though 
user written program. As an example, E-utilities provides many example 
scripts to obtain customized data by constructing user defined pipeline over 
its database. 
 
After data integration, standardized data will be organized based on the 
schema for efficient and effective data creation, storage and manipulation. 
Formal definitions of all the included information in a database, a couple of 
relational tables of relevant data and the relationship among them will be 
established. In these relation tables, certain fields may be designated as keys, 
by which the separated tables can be linked together for facilitating to search 
specific values of that field. Primary key uniquely identifies each record in 
the table. Foreign key matching the primary key of other tables can be used 
to cross-reference tables. 
 
2.1.4 Database management system 
After database construction, the database should be organized and managed 
effectively by Database Management System (DBMS). DBMS is a couple of 
programs and tools that used to store, maintain, and extract information from 
a database [127]. There are several DBMS software available e.g. Oracle, 
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Microsoft SQL Server, Access, MySQL and PostgreSQL. In this work, 
Oracle and Access based relational database management systems have been 
built to manage involving define, create and modify the various information 
as well as privilege. By using Structured Query Language (SQL) queries, all 
entry data from the related tables can therefore be retrieved together for 
display and output. 
 
2.1.5 User Interface 
A web based user interface allows the user to submit query, obtain data and 
interact with database. Without user interface, the database is less useful to 
end user even if the database is complete, well organized and maintained. A 
good database interface can help the user get information stored in database 
quickly and convenient as well as multi-level search capability. A bad 
interface will cause difficulty in searching, locating and displaying data. 
There are two main categories of web based user interface: static web pages 
and dynamic web pages. 
 
Static web pages are also called flat page or stationary page. In contrast to 
dynamic webpage, static web pages are delivered to user exactly as stored 
and the same information to all users. They are usually HTML document 
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files stored in the file system and are available through the HTTP web 
service. Dynamic pages present various content to different users according 
to the parameters provided by them. Dynamic pages are often produced by 
Common Gateway Interface (CGI) with the assistant of server-side 
languages such as Active Server Pages (ASP), Java Server Pages (JSP), Perl, 
Hypertext Preprocessor (PHP) and other languages. The client side dynamic 
web page creation is generally achieved through JavaScript or ActionScript. 
 
In this work, ASP technology is used for server side dynamic web page 
creation and JavaScript is used for client side dynamic web page creation. 
Server side dynamic web page generation over database includes submission 
of user customized query to web server which further interacts with DBMS 
such as MySQL and Oracle. The client side technology is based on Internet 
browsers with support of JavaScript e.g. Internet Explorer, Mozzila Firefox 
and Google Chrome to extract and display the data. The client side dynamic 
web page is generally used to present content more friendly and convenient 
such as change in color or short string tips when mouse is on or off some part 
of the content. 
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2.2 Dataset collection and preprocess for building models 
2.2.1 Dataset resource 
Currently, massive amount of data about small molecules and their related 
annotation information have been accumulated in scientific literatures and 
cheminiformatics databases. Table 1-5 lists some of the widely known small 
molecule databases. For instance, BindingDB is a public, web-accessible 
database of measured binding affinities, focusing chiefly on the interactions 
of protein targets with small drug-like molecules. DrugBank is also a unique 
bioinformatics and cheminformatics resource that combines detailed drug 
(i.e. chemical, pharmacological and pharmaceutical) data with 
comprehensive drug target (i.e. sequence, structure, and pathway) 
information. MDDR is a database covering the patent literature, journals, 
meetings and congresses produced by Symyx and Prous Science. 
 
The datasets used in this work mainly are retrieved from the following two 
types of sources. First, we collected small molecular data from credible 
journals such as Bioorganic & Medicinal Chemistry Letters, Bioorganic & 
Medicinal Chemistry, European Journal of Medicinal Chemistry, European 
Journal of Organic Chemistry and Journal of Medicinal Chemistry, etc. 
Second, we use cheminformatics databases that contain accurate and reliable 
data such as PubChem and ChEMBL [128]. 
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2.2.2 Dataset quality 
The sufficient and high quality data with low experimental errors is 
important for the development of reliable machine learning classification 
model which depends on the quality and quantity of data. Many factors such 
as quality, size and relevance of the dataset can affect machine learning 
process greatly. The data quality is usually assessed during the produce of 
data collection. The data collected from less credit resource will lead to 
faulty models which will induce weak predictive power or even wrong 
prediction. Ideally, the measurements of pharmacological data properties 
should be conducted with a same protocol so that there is a common ground 
to compare different compounds with each other. However, some 
pharmacological properties measurements have been used only for a limited 
number of compounds and most pharmacological properties measurements 
are rarely determined by the same protocol. Thus the collected data consist 
of compound data measured by different protocols and the incorporation of 
additional experimental information. To maintain the stability of data quality, 
in this work, several methods are adopted to ensure that inter-laboratory 
variations caused by different experimental protocols do not significantly 
affect the quality of the training sets. The pharmacological property 
measurements for data were investigated and the ones that contain large 
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variations in experimental protocols compared to the majority of the data are 
filtered. It is estimated that the most common range of the pharmacological 
properties measurements for the compounds investigated in more than one 
source was used to select compounds for the different classes [129].  
 
In this work, the data were collected from varied sources. This approach can 
enrich the diversity in the datasets and reduce the potential bias that may arise 
from a monotonic due to the preferences of the researchers. However, since 
the data are presented by independent researchers who don’t share 
pre-existing agreement on their individual data collection. It is likely that there 
is a certain level of redundancy between the datasets from different sources. 
The redundancy could contrarily deduce diversity in the datasets. Therefore, 
compounds are checked for redundancy by comparing exact match of 
chemical descriptors. In this work, scripts are written to find exact match of 
chemical descriptors to remove redundancy from dataset. 
 
2.2.3 Dataset structural diversity 
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Diversity Index (DI) is applied to evaluate the structural diversity of a 
collection of compounds. It is defined as the average value of the similarity 
between pairs of compounds in a dataset [130], 
 
                                  (1) 
where  is a measure of similarity between compounds  and , D is 
the dataset and |D| is set cardinality (number of elements of the set). The dataset 
is more diverse when DI approaches 0. Tanimoto coefficient [131] were used to 
compute  in this study, 
 
               (2) 
where  is the number of descriptors calculated for the compounds in the 
datasets. A compound i is considered to be similar to a known active j in the 
active dataset if the corresponding sim(i,j) value is greater than a cut-off 
value. 
 
2.3 Molecular descriptor 
Molecular descriptors are frequently used to quantitatively represent various 
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computational studies small molecules. A descriptor is the final result of a 
logical and mathematical procedure which transforms chemical information 
encoded within a symbolic representation of a compound into a useful 
number or the result of some standardized experiment. Molecular descriptors 
have been extensively used in deriving structure-activity relationships [132, 
133], quantitative structure activity relationships [134, 135], and machine 
learning prediction models for pharmaceutical agents [136-143]. They 
represent compounds in the form of mathematical vectors. This 
transformation enables the statistical analysis of chemical compounds. 
 
A number of programs e.g. DRAGON[144], Molconn-Z[145], MODEL[146], 
Chemistry Development Kit(CDK) [147, 148], JOELib [149], and Xue 
descriptor set [140] are available to calculate chemical descriptors. These 
methods can be used for deriving >3,000 molecular descriptors including 
constitutional descriptors, topological descriptors, RDF descriptors [150], 
molecular walk counts [151], 3D-MoRSE descriptors [152], BCUT 
descriptors [153], WHIM descriptors [154], Galvez topological charge 
indices and charge descriptors [155], GETAWAY descriptors [156], 2D 
autocorrelations, functional groups, atom-centred descriptors, aromaticity 
indices [157], Randic molecular profiles [158], electrotopological state 
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descriptors [159], linear solvation energy relationship descriptors [160], and 
other empirical and molecular properties. Not all of the available descriptors 
are needed for representing features of a particular class of compounds. 
Moreover, without properly selecting the appropriate set of descriptors, the 
performance of a developed machine learning VS tool may be affected to 
some degrees due to the noise arising from the high redundancy and 
overlapping of the available descriptors. 
 
In this work, 98 1D and 2D descriptors are computed which are widely used 
in machine learning based virtual screening models. These 98 descriptors 
were selected from the descriptors derived from MODEL program by 
discarding those that were redundant and unrelated to the problem studied 
here. These 98 descriptors are showed in Table 2-1. 
 
Table 2-1 98 molecular descriptors used in this work. 






18 Number of C,N,O,P,S, Number of total atoms, Number of  rings, 
Number of bonds, Number of non-H bonds, Molecular weight,, 
Number of rotatable bonds, number of H-bond donors, number of 
H-bond acceptors, Number of 5-member aromatic rings, Number of 
6-member aromatic rings, Number of N heterocyclic rings, Number 
  44 
of O heterocyclic rings, Number of S heterocyclic rings. 
Chemical 
properties 




35 Schultz molecular topological index, Gutman molecular topological 
index, Wiener index, Harary index, Gravitational topological index, 
Molecular path count of length 1-6, Total path count, Balaban Index 
J, 0-2th valence connectivity index, 0-2th order delta chi index, 
Pogliani index, 0-2th Solvation connectivity index, 1-3th order Kier 
shape index, 1-3th order Kappa alpha shape index, Kier Molecular 
Flexibility Index, Topological radius, Graph-theoretical shape 
coefficient, Eccentricity, Centralization, Logp from connectivity. 
Electro-topological 
state 
42 Sum of Estate of atom type sCH3, dCH2, ssCH2, dsCH, aaCH, 
sssCH, dssC, aasC, aaaC, sssC, sNH3, sNH2, ssNH2, dNH, ssNH, 
aaNH, dsN, aaN, sssN, ddsN, aOH, sOH, ssO, sSH; Sum of Estate 
of all heavy atoms, all C atoms, all hetero atoms, Sum of Estate of 
H-bond acceptors, Sum of H Estate of atom type HsOH, HdNH, 
HsSH, HsNH2, HssNH, HaaNH, HtCH, HdCH2, HdsCH, HaaCH, 
HCsats, HCsatu, Havin, Sum of H Estate of H-bond donors 
In this work, the 2D structure of each of the compounds was generated by 
using ChemDraw [106] or downloaded from databases such as PubChem and 
BindingDB [161]. Then they were subsequently converted into 3D structure 
by using CORINA [162]. The 3D structure of each compound was manually 
inspected to ensure the proper chirality of each chiral agent. All salts and 
elements, such as sodium or calcium, were removed prior to descriptor 
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calculation. The optimization of generated geometries was conducted 
without symmetry restrictions. The 3D structures of the compounds then 
were used to compute the molecular descriptors by the in-house programs 
and scripts. 
 
2.4 Scaling of molecular descriptors 
Molecular descriptors are usually scaled before they can be employed for 
machine learning methods. Scaling of chemical descriptors ensures that each 
of descriptor have unbiased contribution in constructing the prediction 
models[163]. Scaling can be done by various of ways e.g. auto-scaling, range 
scaling, Pareto scaling [164], and feature weighting [165, 166]. In this work, 
range scaling is used to scale the chemical descriptor data. Range scaling is 
done by dividing the difference between descriptor value and the minimum 
value of that descriptor with the range of that descriptor: 
𝑑𝑖𝑗
𝑠𝑐𝑎𝑙𝑒𝑑 = 𝑑𝑖𝑗−𝑑𝑗,𝑚𝑖𝑛
𝑑𝑗,𝑚𝑎𝑥−𝑑𝑗,𝑚𝑖𝑛                                (3) 
where 𝑑𝑖𝑗𝑠𝑐𝑎𝑙𝑒𝑑, 𝑑𝑖𝑗 ij , 𝑑𝑗,𝑚𝑎𝑥 and 𝑑𝑗,𝑚𝑖𝑛 are the scale descriptor value of 
compound i, absolute descriptor value of compound i, maximum and 
minimum  values of descriptor  j respectively. The scaled descriptor value 
falls in the range of 0 and 1.  
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2.5 Machine learning classification methods 
A machine learning (ML) method takes a training set of objects that have 
previously been classified into two or more classes as input. 
 
Machine learning classification methods employ computational and statistical 
methods to construct mathematical models from a training set of objects which 
is used to classify independent test sample. The training samples are represented 
by vectors which can binary, categorical or continuous. Machine learning can be 
divided into two types: Supervised and Unsupervised. Supervised machine 
learning, as the name indicates, generally needs feeding which generally involve 
already labeled or classified training data. Example of supervised machine 
learning includes SVM, ANN, Decision tree learning, Inductive logic 
programming, Boosting, Gaussian process regression etc. Unsupervised 
machine learning, as the name indicates, gets unlabeled training data and the 
learning task involve to find the organization of data. Examples of unsupervised 
machine learning include Clustering, Adaptive Resonance Theory, and Self 
Organized Map (SOM). Some of machine learning methods employed in this 
work are SVM, PNN, kNN. They are explained below in subsequent sub 
sections. For a comparative study, Tanimoto similarity searching method is 
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also introduced. Websites for codes of some machine learning methods are 
given in Table 2-2.  
 







k Nearest Neighbor  http://www.cs.cmu.edu/~zhuxj/courseproject/knndemo/KNN.html 
PERL Module for 
KNN 
http://aspn.activestate.com/ASPN/CodeDoc/AI-Categorize/AI/Categorize/kNN.html 















NeuralWorks Predict http://www.neuralware.com/products.jsp 
NeuroShell Predictor http://www.mbaware.com/neurpred.html 
SVM 
SVM light http://svmlight.joachims.org/ 
LIBSVM http://www.csie.ntu.edu.tw/~cjlin/libsvm/ 
mySVM http://www-ai.cs.uni-dortmund.de/SOFTWARE/MYSVM/index.html 
BSVM  http://www.csie.ntu.edu.tw/~cjlin/bsvm/ 
SVMTorch http://www.idiap.ch/learning/SVMTorch.html 
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2.5.1 Support vector machine (SVM) 
Support vector machine (SVM) is based on the structural risk minimization 
principle of statistical learning theory [167, 168], which consistently shows 
outstanding classification performance, is less penalized by sample 
redundancy, and has lower risk for over-fitting [169, 170]. 
 
In linearly separable cases, SVM constructs a hyper-plane to separate active 
and inactive classes of compounds with a maximum margin. A compound is 
represented by a vector xi composed of its molecular descriptors. The 
hyper-plane is constructed by finding another vector w and a parameter b 
that minimizes 2w  and satisfies the following conditions: 
 1,  for 1i ib y⋅ + ≥ + = +w x  Class 1 (active)   (4) 
 1,  for 1i ib y⋅ + ≤ − = −w x  Class 2 (inactive)  (5) 
where yi is the class index, w is a vector normal to the hyperplane, /b w  
is the perpendicular distance from the hyperplane to the origin and 2w  is 
the Euclidean norm of w. Based on w and b, a given vector x can be 
classified by f(x) = [( ) ]sign b⋅ +w x . A positive or negative f(x) value 
indicates that the vector x belongs to the active or inactive class respectively.  
In nonlinearly separable cases, which almost always occur in classifying 
compounds of diverse structures [111, 171-177], SVM maps the input 
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vectors into a higher dimensional feature space by using a kernel function 
K(xi, xj). We used RBF kernel 
2 2/ 2( , ) j ii jK e
σ− −= x xx x which has been 
extensively used and consistently shown better performance than other 
kernel functions [178-180]. Linear SVM can then applied to this feature 
space based on the following decision function: 
0
1




f sign y K bα
=
= +∑x x x , where the coefficients αi0 and b are 
determined by maximizing the following Langrangian expression: 
1 1 1
1 ( , )
2
l l l
i i j i j i j
i i j
y y Kα α α
= = =








0α . A positive or negative f(x) value indicates that the vector x 
belongs to the active or inactive class respectively. For a given training set of 
instance-label pairs (xi, yi), i=1, …,l where xi ∈Rn and yi ∈ { 1, −1 }inl , in 
SVM, the task of finding the hyper-plane which is able to separate active and 
inactive classes with a maximum margin, in essence, is to look for the 
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In developing our SVM VS tool, a hard margin C=100,000 was used. The 
margin parameter C is penalty parameter that controls the trade-off between 
the training errors and sample separation. Increasing C imposes a higher 
penalty for training errors. Our chosen value corresponds to a very high 
penalty. Software LibSVM [181], an integrated software for support vector 
classification, regression and distribution estimation, was chosen to do the 
machine learning in this work. 
The process of training and using a SVM VS model for screening 
compounds based on their molecular descriptors is schematically illustrated 
in Figure 2-1. 
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Figure 2-1 Schematic diagram of the process of the training a prediction model and using it 
for predicting active compounds of a compound class from their structurally-derived 
properties (molecular descriptors) by using support vector machines; A, B, E, F and (hj, pj, 
vj,…) represents such structural and physicochemical properties as hydrophobicity, volume, 
polarizability, etc. 
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2.5.2 k-nearest neighbors (kNN) 
kNN measures the Euclidean distance 2iD = −x x  between a compound x 
and each individual inhibitor or non-inhibitor xi in the training set[182, 183]. 
A total of k number of vectors nearest to the vector x are used to determine the 
decision function f(x): 
1






← ∑x x                                    (6) 
where ( , ) 1 if  and ( , ) 0 if a b a b a b a bδ δ= = = ≠  , arg max is the maximum 
of the function, V is a finite set of vectors {v1,...,vs}  and ˆ ( )f x  is an 
estimate of f(x). Here estimate refers to the class of the majority compound 
group (i.e. inhibitors or non-inhibitors) of the k nearest neighbors. The 
procedure of kNN is illustrated in Figure 2-2. 
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Figure 2-2 Schematic diagram illustrating the process of the prediction of compounds of a 
particular property from their structure by using k-nearest neighbors (kNN). Feature vector 
(hj, pj, vj,…) represents such structural and physicochemical properties as hydrophobicity, 
volume, polarizability, etc; green dots: agents with the property; black box : agents without 
the property. 
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2.5.3 Probabilistic neural network (PNN) 
Probabilistic neural network (PNN) belongs to the neural network methods. 
It is designed for classification through the use of Bayes’ optimal decision 
rule [129]: ( ) ( )i i i j j jh c f h c f>x x , where hi and hj are the prior probabilities, ci 
and cj are the costs of misclassification and fi(x) and fj(x) are the probability 
density function for class i and j respectively. An unclassified vector x is 
classified into population i if the product of all the three terms is greater for 
class i than for any other class j (not equal to i). In most applications, the 
prior probabilities and costs of misclassifications are treated as being equal. 
The probability density function for each class for a univariate case can be 
estimated by using the Parzen’s nonparametric estimator[184], 
           
1







= ∑ x xx                  (7) 
where n is the sample size, σ is a scaling parameter which defines the width 
of the bell curve that surrounds each sample point, W(d) is a weight function 
which has its largest value at d = 0 and (x – xi) is the distance between the 
unknown vector and a vector in the training set. The Parzen’s nonparametric 
estimator was later expanded by Cacoullos for the multivariate case. 
      ,1 1,1
11 1






g x x W
nσ σ σ σ=
−−
= ∑         (8) 
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The Gaussian function is frequently used as the weight function because it is 
well behaved, easily calculated and satisfies the conditions required by 
Parzen’s estimator. Thus the probability density function for the multivariate 
case becomes 
           
2
1 1








= −   
 
∑ ∑x         (9) 
The network architectures of PNN are determined by the number of 
compounds and descriptors in the training set. PNN are constituted of four 
layers, the input layer, the pattern layer, the summation layer and the output 
layer. The input layer provides input values to all neurons in the pattern layer 
and has as many neurons as the number of descriptors in the training set. The 
number of pattern neurons is determined by the total number of compounds in 
the training set. Each pattern neuron computes a distance measure between the 
input and the training case represented by that neuron and then subjects the 
distance measure to the Parzen’s nonparametric estimator. The summation 
layer has a neuron for each class and the neurons sum all the pattern neurons’ 
output corresponding to members of that summation neuron’s class to obtain 
the estimated probability density function for that class. Finally, the single 
neuron in the output layer then estimates the class of the unknown vector x by 
comparing all the probability density function from the summation neurons 
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and choosing the class with the highest probability density function. Figure 
2-3 illustrates the procedure of PNN method. 
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Figure 2-3 Schematic diagram illustrating the process of the prediction of compounds of a 
particular property from their structure by using probabilistic neural networks (PNN). A, B: 
feature vectors of agents with the property; E, F: feature vectors of agents without the 
property; feature vector (hj, pj, vj,…) represents such structural and physicochemical 
properties as hydrophobicity, volume, polarizability, etc.  
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2.5.4 Tanimoto similarity searching method 
Determining if two compounds are similar to each other or not in a training 
dataset can be conducted by using the Tanimoto coefficient sim(i,j) [131] 
               (10)
 
where l is the number of molecular descriptors. A compound i is considered to 
be similar to a known active j in the active dataset if the corresponding sim(i,j) 
value is greater than a cut-off value. In this work, in computing sim(i,j), the 
molecular descriptor vectors xis were scaled with respect to all of the MDDR. 
The cut-off values for similarity compounds are typically in the range of 0.8 to 
0.9 [185, 186]. A stricter cut-off value of 0.9 was used in this work. 
 
2.5.5 Generation of putative negatives 
Both positive data (e.g. active compounds) and negative data (e.g. inactive 
compounds) are compulsory for building machine learning prediction models. 
As for prediction of compound inhibitors, positives can be formed from 
known active compounds but negatives are usually lacking. Previous studies 
have used known inactive compounds and active compounds of other 
biological target classes as putative inactive compounds [87, 111, 171-174, 
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inactive proteins in SVM classification of various functional classes of 
proteins [189-191] has been attempted for generating putative inactive 
compounds[114]. An advantage of this approach is its independence on the 
knowledge of known inactive compounds and active compounds of other 
biological target classes, which enables more expanded coverage of the 
“inactive” chemical space in cases of limited knowledge of inactive 
compounds and compounds of other biological classes. A drawback of this 
approach is the possible inclusion of some yet-to-be-discovered active 
compounds in the “inactive” class, which may affect the capability of SVM 
for identifying novel active compounds. As has been demonstrated in an 
earlier study[114], such an adverse effect is expected to be relatively small 
for many biological target classes. In applying this approach to proteins, all 
known proteins are clustered into ~8,933 protein domain families in based on 
the clustering of their amino acid sequences [149], and a set of putative 
inactive proteins can be tentatively extracted from a few representative 
proteins in those families without a single known active protein. 
Undiscovered active proteins of a specific functional class typically cover no 
more than a few hundred families, which gives a maximum possible “wrong” 
family representation rate of <10.2% even when all of the undiscovered 
active proteins are misplaced into the inactive class [192]. Importantly, 
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inclusion of the representative of a “wrong” family into the inactive class 
does not preclude other active family members from being classified as 
active. Statistically, a substantial percentage of active members can be 
classified by ML methods as active even if its family representative is in the 
inactive class [114, 192]. Therefore, in principle, a reasonably good SVM 
classification model can be derived from these putative inactive samples, 
which has been confirmed by a number of studies of proteins [189-192]. 
 
In a similar manner, known compounds can be grouped into compound 
families by clustering them in the chemical space defined by their molecular 
descriptors [193, 194]. As SVM predict compound activities based on their 
molecular descriptors, in developing SVM VS tools, it makes sense to cluster 
as well as to represent compounds in terms of molecular descriptors. By 
using a K-means method [193, 194] and molecular descriptors computed 
from our own software [195], we generated 8,423 compound families from 
the 13.56M compounds in the PUBCHEM and MDDR databases that we 
were able to compute the molecular descriptors, which is consistent with the 
12,800 compound-occupying neurons (regions of topologically close 
structures) for 26.4 million compounds of up to 11 atoms [65], and the 2,851 
clusters for 171,045 natural products [196]. 
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The number of compound inhibitors of a specific target is usually around 
1000 and distributed in several hundred families respectively.  Because of 
the extensive effort in searching the known compound libraries for 
identifying active compounds in these target classes, the number of 
undiscovered “active” families in PUBCHEM database is expected to be 
relatively small, most likely no more than several hundred families. The ratio 
of the discovered and undiscovered “active” families (hundreds) and the 
families that contain no known active compound (~8423 based on the current 
versions of PUBCHEM and MDDR) for these and possibly many other 
target classes is expected to be <15%. Therefore, putative inactive training 
datasets can be generated by extracting a few representative compounds of 
those families that contain no known active compound in the active training 
set, with a maximum possible “wrong” family representation rate of <15% 
even when all of the undiscovered active compounds are misplaced into the 
inactive class, and with the expectation that a substantial percentage of active 
members in the putative “inactive” families can be classified as active 
despite of their family representatives are placed into the inactive training 
sets. As has been shown in a study of SVM VS tools, a substantial 
percentage of identified virtual hits are from these “inactive” families [114]. 
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2.6 Virtual screening model optimization, validation 
and performance measurements 
2.6.1 Model optimization and validation 
In-silico modeling offers the prediction of the pharmacological properties of 
compounds which have not been clinically or biologically tested. Therefore it 
is important to estimate and validate the predicting ability of the 
pharmacological-data-derived models by their performances with the 
compounds that are not present in the training set. In this work, 5-fold 
cross-validation and independent validation datasets were used for this 
purpose. In 5-fold cross-validation, compounds are randomly divided into five 
subsets of approximately equal size. Four subsets are used as the training set 
for developing a model; the remaining one is used as a testing set for 
evaluating the prediction performance of the model. This procedure is 
repeated five times such that every subset is used as a testing set once. 
Through this procedure, the optimal parameter can be obtained. Models have 
types of parameters that must be optimized. In this work, SVM is trained by 
using a radial basis function kernel which has an adjustable parameter σ. For 
PNN, the only parameter to be optimized is a scaling parameter σ. In kNN, the 
optimum number of nearest neighbors, k, needs to be derived for each training 
set. Optimization of the parameter for each of these methods is conducted by 
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scanning the parameter through a range of values. The average accuracy of the 
five time models is seen as the accuracy predicting capability of the model 
constructed with the machine learning method. Five-fold cross-validation can 
reflect the average performance of a model, however, it has the tendency of 
underestimating the prediction capability of a classification model, especially 
if important molecular features happen to be contained only in a minority of 
the compounds in the training set [197, 198]. Hence if a model has relatively 
low cross-validation accuracy, it can still be predictive [197]. Therefore, 
cross-validation alone is not decisive to the performance of a model. To 
complement cross-validation, independent validation datasets are used. They 
may provide a more reliable estimation of the prediction capability of a 
pharmacological property prediction model [199, 200]. The independent 
validation dataset should be strictly independent from the training.  
 
2.6.2 Performance evaluation 
Measurements such as sensitivity, specificity and the overall prediction 
accuracy are employed to quantitatively assess the performance of virtual 
screening models. They are defined in terms of true positives TP 
(pharmaceutical agents possessing a specific pharmacological property), true 
negatives TN (pharmaceutical agents not possessing a specific 
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pharmacological property), false positives FP (pharmaceutical agents not 
possessing a specific pharmacological property but predicted as agents 
possessing the specific pharmacological property) and false negatives FN 
(pharmaceutical agents possessing a specific pharmacological property but 
predicted as agents not possessing the specific pharmacological property). 
Sensitivity and specificity are the measurement of prediction accuracy for 
pharmaceutical agents possessing a specific pharmacological property and 
agents not possessing that pharmacological property respectively. The 
overall prediction accuracy (Q) and Matthews correlation coefficient (MCC) 
[201] are used to measure the overall prediction performance. They are 
defined as follows: 
                                         (11) 
                                         (12) 
                                  (13) 
              (14) 
The typical measurements of a model performance in screening large libraries 
include [202] yield (percentage of known positives predicted as virtual hits), 
hit-rate (percentage of virtual hits that are known positives), false hit-rate 
(percentage of virtual hits that are known negatives) and enrichment factor EF 
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Yield = SE                                            (15) 
Hit-rate = TP/(TP+FP)                                  (16) 
False hit-rate = FP/(TP+FP)                              (17) 
Enrichment factor EF = hit-rate / (TP+FN)/(TP+FN+TN+FP)   (18) 
 
2.6.3 Overfitting problem and its detection 
Overfitting is a major concern in machine learning classification methods. It 
happens when a model that agrees well with the observed data but has no 
predictive ability, which means it does not have any value to unseen or future 
data. There are two main types of overfitting situations: (1) a model more 
flexible than it needs to be and (2) a model including irrelevant descriptors 
[198]. An over-fitted classification system tends to obtain much higher 
prediction accuracies in the cross-validation sets than in the independent 
validation sets. Hence frequently used method for checking whether a model is 
overfitted is to compare the prediction accuracies in the cross-validation 
procedure with those found in testing independent validation sets [198]. 
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Chapter 3 Development of MicrobPad MD: microbial 
pathogen diagnostic methods database  
 
3.1 Introduction 
Medical pathogens of bacterial, fungal, and viral species induce infections，illnesses 
and sometimes serious medical conditions in the infected hosts [35, 36, 203, 204]. 
Diagnosis of these pathogens is important for proper treatment and investigation of 
pathogenesis processes, and extensive efforts have been made for developing 
molecular techniques that enable fast, accurate, sensitive and low-cost diagnosis of 
these pathogens [33-36]. Based on these molecular techniques, advanced diagnostic 
devices have been developed for a number of medical pathogens [35, 205]. More 
devices are needed for comprehensive coverage and faster diagnosis of medical 
pathogens, and for direct detection of multiple species [33, 205, 206]. 
 
Several databases have been developed and explored for providing the information 
and tools about the molecular diagnostic methods of specific classes of pathogenic 
species. For instance, the RIDOM website provides medical micro-organism 
differentiation services based on the analysis of small subunit ribosomal 16S rDNA 
sequences [207]. An expanded MicroSeq 500 16S rDNA sequence library database 
[208] and an integrated database network system [209] are useful for the identification 
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of nocardia species. The fourth international spoligotyping database [210] has been 
explored for the identification of mycobacterium species. A three-locus DNA 
sequence database is useful for the identification of the 69 Fusarium species 
associated with human or animal mycoses [211]. The 16SpathDB database supports 
automated identification of medically important bacteria by 16S rRNA gene 
sequencing [212]. Another database provides pulsed-field gel electrophoresis patterns 
of epidemic-type oxacillin-resistant Staphylococcus aureus strains [213]. 
GenoBASE-pylori is useful for genotype searching of the human gastric pathogen 
Helicobacter pylori [214]. TrED is a relational database that provides integrated 
access to various expression data of Trichophyton rubrum for developing effective 
diagnostic and treatment strategies [215]. 
 
These databases and web-tools are highly useful for the development of diagnostic 
devices of specific classes of medical pathogens. To facilitate the development of 
diagnostic devices for more diverse groups of medical pathogens, a database with 
integrated information about diagnostic methods, targets, and primers/probes for the 
known bacterial, fungal and viral pathogens is needed. Therefore, we developed the 
Microbial pathogen diagnostic methods database, MicrobPad MD 
(http://bidd.nus.edu.sg/group/MicrobPad/MicrobPad.asp or 
http://pha-bidd.nus.edu.sg/group/MicrobPad/MicrobPad.asp), to provide 
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comprehensive information about the molecular diagnostic techniques, targets, 
primers/probes, detection procedures and conditions, and tested diagnostic accuracies 
and limit of diagnosis for 314 bacterial, fungal and viral species from 61 genera.  
 
3.2 Database construction 
MicrobPad MD is intended as a comprehensive resource for facilitating the research, 
development, and evaluation of molecular diagnostic methods for faster detection of 
pathogens that conventional diagnostic methods are inadequate to meet the treatment 
demand. For instance, more than half of the Tuberculous meningitis (TB) cases cannot 
be confirmed microbiologically and the conventional diagnostic method CSF takes 
over two weeks time for the test outcome, resulting in many patients being treated on 
the basis of clinical suspicion before the diagnosis is confirmed [216]. Partly for 
dealing with this problem, two PCR-based molecular diagnostic devices, TB 
Amplicor and E-MTD, have been developed and approved by the FDA for diagnosis 
of TB from clinical specimens [217]. 
 
In addition to the development of MicrobPad MD as a resource for microbial 
pathogen diagnostic methods, we also aim to provide additional information useful for 
understanding the characteristics and mechanisms of the microbial pathogens. These 
include pathogen strains and hosts, tissue distribution or habitats, cultivation methods, 
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biochemical characteristics, virulence factors, morphology, diseases, symptoms, 
treatment and prevention methods are provided for facilitating the study of the 
molecular mechanisms of medical pathogens. Cross-links to the NCBI genome and 
SwissProt/UniProt databases are provided. 
 
MicrobPad MD is a freely accessible public online database and the full version of the 
database in text format can also be downed from the download page. Users are 
recommended to use the web-version because of its user friendly format. Our 
database continues to be regularly updated and supported. Queries and suggestions are 
welcome and can be sent via email link provided in the MicrobPad MD webpage. 
Users are also welcome to send their new data via email or the new data upload page. 
 
3.3 Data collection and access 
The relevant data were collected from the literature searched from the Pubmed 
database [218] by using keyword combinations of “diagnosis”, “diagnostic”, 
“detection”, “detect”, “bacterial”, “fungal” and “microbial”, “viral”, “pathogen”, and 
“pathogenetic”, and from the information described in such review journals as Expert 
Rev Mol Diagn, Nature Rev Microbiology, and Trends in Biotechnology (The journal 
titles were listed in the Appendix A). A total of 382 papers were collected, which 
report or describe the molecular diagnostic methods, gene targets, primers/probes, 
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detection procedures and conditions, and the tested diagnostic accuracies and limit of 
diagnosis for 205 bacterial species from 25 bacteria genera, 17 fungal species from 6 
fungal genera, and 92 viral species from 30 virus genera. We further extracted the 
information from these papers and additional literature searched from Pubmed [218] 
for finding the pathogen strains and hosts, tissue distribution or habitats, cultivation 
methods, biochemical characteristics, virulence factors, morphology, diseases, 
symptoms, treatment and prevention methods for each species. 
 
The MicrobPad MD data can be accessed by keyword or customized search. The 
keyword search is case insensitive and wildcards are supported. In a query, a user can 
specify full name or any part of the name in a text field. Wild characters of '*' and '?' 
are allowed in text field. Here, '?' represents any one character and '*' represents a 
string of characters of any length. For example, input of 'toxin' in the query field finds 
entries containing 'toxin' in their names, such as alpha toxin, beta toxin, epsilon toxin, 
RTX toxin, enterotoxins, etc. On the other hand, input of 'Clostridium*' finds all the 
species start their genus names with 'Clostridium'. In this case, '*' represents 
'perfringens A' , 'perfringens B', 'septicum', 'difficile', etc. 
 
Figure 3-1 shows the home page of the database. Customized search (Figure 3-2) 
fields include genus name, species name, target name, disease indication and 
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virulence factor. The result of a search is illustrated in Figure 3-3, in which all entries 
that satisfy the search criteria are listed. This list includes the MicrobPad entry ID, 
genus name, species name, virulence factor, target gene, disease indications, and the 
number of diagnostic methods. The related species and diagnosis method page 
(Figure 3-4) can be obtained by clicking the “MicrobPad ID” link of a selected 
MicrobPad entry. The page of species and diagnostic method contains two sections. 
The first and second section provides detailed description about the medical species 
and the diagnostic methods respectively. Further information about the genome of the 
species, target genes and virulence factors can be accessed via crosslink to NCBI 
genome databases [218] and SwissProt/UniProt database [219]. The whole MicrobPad 
methods data can be downloaded via the download link as showed in Figure 3-5. It 
also allow users to contribute to the database by uploading data in certain format 
illustrated in Figure 3-6. 
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Figure 3-1 Home page of MicrobPad MD database 
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Figure 3-2 Customized search page. This page provides search fields of genus name, species 
name, target name, disease indication and virulence factor. 
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Figure 3-3 List result page. This page provides genus name, species name, virulence factor, 
target gene, disease indications, and the number of diagnostic methods. 
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Figure 3-4 Related species and diagnostic methods page. This page provides detailed 
description about the related species and the diagnostic methods. 
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Figure 3-5 Data download page of MicrobPad MD database 
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Figure 3-6 Data upload page of MicrobPad MD database 
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3.4 Database usage and validation 
Users of MicrobPad MD are expected to have basic knowledge about the popular 
molecular diagnostic techniques such as PCR, Multiplex PCR, real-time PCR, the 
diagnostic markers of microbial pathogens including the targets, primers, and probes, 
and the commonly used detection procedures. To facilitate the users for studying the 
relevant techniques, all the techniques used in the diagnostic methods described in the 
MicrobPad MD are provided in the help page. For searching MicrobPad MD, users 
are also expected to have the knowledge of at least one of the following items: 
pathogen genus name, pathogen species name, virulence factor, detection target name, 
and disease indication. Users can use both keyword search and browsing facilities 
(with pull-down manuals of pathogen, Target Name, Disease Indication and Virulence 
Factor lists) for selecting the relevant diagnostic method. Keyword search function 
supports incomplete word search such that all items that partially match the input 
keywords are displayed for user to select appropriate entries. Our database is built 
based on IIS HTTP server, ASP (Microsoft's server-side script engine for dynamically 
generated web pages) and Access (Microsoft's database manage system). There is no 
special requirement for client users. It can be easily accessed on various operation 
systems by common Internet Browsers such as Internet Explorer, Chrome, Firefox 
and Safari. 
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As an illustrative example, in order to find the diagnostic method for detecting the 
disease “Brucellosis” from clinical samples, the keyword “Brucellosis” can be entered 
into the MicrobPad MD keyword search field, and the search leads to the list of 
species and corresponding molecular diagnostic method, specifically the 8 species and 
the 17 methods. After obtaining the relevant information, users are expected to 
prepare the primer/probe, DNA polymerase and other necessary reagents, and use 
PCR amplifier and other relevant equipments for developing diagnostic tools.  
 
Validation study was conducted on a molecule diagnostic method for detecting 
Mycobacterium tuberculosis. It has been reported that the Mycobacterium 
tuberculosis speciﬁc probe KY172-T3 (59-GGTGGAAAGCGCTTTAGCGGT-39) 
has been selected from a hypervariable region within the 16S rRNA gene that are 
conserved among mycobacterial species [220]. The sequence of these probe and 
sequence was used for searching all similarity sequences in 16S ribosomal RNA 
sequences (Bacteria and Archaea) database by using NCBI blast 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) The sequence of Mycobacterium tuberculosis 
strain NCTC 7416 H37Rv 16S ribosomal RNA is one of the top-6 hits among 123 
Blast Hits with max score 42.1, total score 62.4, query coverage 100%, e value 2e-05 
and max ident 100%. Base on this probe, Roche AMPLICOR for Mycobacterium 
tuberculosis PCR test (TB AMPLICOR) has been developed which is a rapid 
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diagnostic test and has been shown in clinical tests to have a sensitivity of 66.7% and 
a specificity of 99.6% [221]. 
 
3.5 Concluding remarks 
Extensive studies of medical pathogens have led to the identification of high numbers 
of molecular diagnosis signatures and their recognition techniques useful for the 
development of fast and low cost pathogen diagnostic tools [35, 36, 203-205]. While 
significant progress has been made in developing molecular diagnostic devices [35, 
205], new methods of rapid diagnosis of infectious pathogens are still in urgently 
demand, particularly for such serious infections such as septic shock wherein the 
survival rates degrease on hourly basis if appropriate treatment is delayed [206]. 
General databases such as MicrobPad MD and the specialized databases such as 
RIDOM [207], MicroSeq 500 16S rDNA sequence library [208], the fourth 
international spoligotyping [210], 16SpathDB [212], GenoBASE-pylori [214], and 
TrED [215] are useful resources and tools for facilitating the development of new 
diagnostic devices. New technologies, such as mass spectrometry [222], 
next-generation sequencing [223] and single-molecule detection methods [224, 225], 
in combination with existing diagnostic technologies [35, 36, 203-205] and 
knowledge of antimicrobial resistances [226], are expected to further improve the 
speed and precision of the identification of infectious organisms and the 
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determination of their sensitivities to antimicrobial agents [205, 206, 227]. The new 
methods and data can be added into MicrobPad MD and other databases to facilitate 
the development of new diagnostic devices for comprehensive sets of medical 
pathogens. 
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Pharmaceutical drugs or agents generally exert their therapeutic effects by 
binding to and subsequently modulating the activity of particular protein, 
nucleic acid or other molecular (such as membrane) targets [228, 229]. Target 
discovery efforts have led to the discovery of hundreds of successful targets 
(targeted by at least one approved/marketed drug), several hundred clinical 
trial targets (targeted by drug in clinical trial but not any approved/marketed 
drug) and more than 1,000 research targets (targeted only by experimental 
drugs only) [58-61]. Rapid advances in genomic, proteomic, structural, 
functional and systems studies of the known targets and other disease proteins 
[230-236] enable the discovery of drugs, multi-target agents, combination 
therapies and new drug targets [58, 61, 230, 237, 238], analysis of on-target 
toxicity [239] and pharmacogenetic responses [240], and development of 
discovery tools [241-244]. 
To facilitate the access of therapeutic targets information, publicly accessible 
databases such as Drugbank [245], Potential Drug Target Database (PDTD) 
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[246] and our own Therapeutic Target Database (TTD) [247] have been 
developed. These databases complement each other to provide target and drug 
profiles. DrugBank is an excellent source for comprehensive drug data with 
information about drug actions and multiple targets [245]. PDTD contains 
active-sites as well as functional information for the potential targets with 
available 3D structures [246] in PDB. TTD provides information about the 
primary therapeutic targets of a comprehensive set of both approved and 
experimental drugs [247]. 
While drugs and agents typically modulate the activities of multiple proteins 
[248] and up to 14,000 drug-targeted-proteins have been published [249], the 
reported number of primary targets directly related to the therapeutic actions 
of approved drugs is limited to 324 [60]. Information about the primary targets 
of more comprehensive sets of approved, clinical trial and experimental drugs 
is highly useful for facilitating focused investigations and discovery efforts 
against the most relevant and proven targets [61, 230, 237, 239, 240, 243]. 
Therefore, we updated TTD by significantly expanding the target data to 
include 348 successful, 292 clinical trial, and 1,254 research targets, and 
added drug data for 1,514 approved, 1,212 clinical trial and 2,302 
experimental drugs linked to their primary targets (3,382 small molecule and 
649 antisense drugs with available structure and sequence). 
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We collected a slightly higher number of successful targets than the reported 
number of 320 targets [60] due to the identification of protein subtypes as the 
targets of some approved drugs and the inclusion of multiple drug targets of 
approved multi-target drugs and non-protein/nucleic acid targets of 
anti-infectious drugs (e.g. bacterial cell wall and membrane components). 
Clinical trial drugs are based on reports since 2005 with the majority since 
2008, their corresponding clinical trial phase is specified. We also added new 
features for data access by drug mode of action, sequence and tanimoto 
similarity search of targets and drugs, customized and whole data download, 
and standardized target ID. TTD is now available online, and can be accessed 
at http://bidd.nus.edu.sg/group/cjttd/TTD.asp. 
4.2 Target and drug data collection and access 
Additional information about the approved, clinical trial and experimental 
drugs and their primary targets were collected by comprehensive search of 
literatures, FDA Drugs of FDA webpage 
(http://www.accessdata.fda.gov/scripts/cder/drugsatfda/) with data about FDA 
approved drugs, latest reports from 17 pharmaceutical companies that describe 
clinical trial and other pipeline drugs (Astrazeneca, Bayer, Boehringer 
Ingelheim, Genentech, GSK, Idenix, Incyte, ISIS, Merck, Novartis, Pfizer, 
Roche, Sanofi Aventis, Schering-Plough, Spectrum, Takeda and Teva). 
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Literature search was conducted by combinational searching the PubMed 
database by using keyword “therapeutic” and “target”, “drug” and “target”, 
“clinical trial” and “drug”, “clinical trial” and “target”, and by searching 
reputable review journal like Nature Reviews Drug Discovery, Drug 
Discovery Today, Current Opinion in Pharmacology, Current Drug Targets, 
Current Topics in Medicinal Chemistry, Science, Mini-Reviews in Medicinal 
Chemistry, Anti-Cancer Agents in Medicinal Chemistry, and so on (The 
journal titles were listed in the Appendix B). In the meantime, we also 
extracted data from 2008 Report of Medicines in Development biotechnology, 
and 2008 Report of Medicines in Development for HIV/AIDS, cancer, 
children, diabetes, neurological disorders, women, and rare diseases, which 
explicitly mentioned the targets and theirs corresponding drugs. In particular, 
these searches identified 198 recent papers reporting approved and clinical 
trial drugs and their targets. As many of the experimental antisense drugs are 
described in US patents, we specifically searched US patent databases to 
identify 745 antisense drugs targeting 104 targets. Primary targets of 211 
drugs and drug binding modes of 79 drugs are not specified in our collected 
documents. Further literature search was conducted to find the relevant 
information for these drugs. The criteria for identifying the primary target of a 
drug or targets of a multi-target drug is based on the developer or literature 
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reported cell-based or in vivo evidence that links the target to the therapeutic 
effect of the drug. These searched documents are listed in the respective target 
or drug entry page of TTD and many cross links are provided for the 
respective PubMed abstracts, US patents, or developer web-page. 
However, in order to double check and have an overall understanding on the 
status of these targets, we have searched from the literature of reported 
IC50/EC50 values against the target/targets and cell-lines and the reports of in 
vivo studies to confirm that the reported primary targets are accurate. 
4.3 Ways to access therapeutic targets database 
TTD data can be accessed by both whole database (Figure 4-1) and 
customized (Figure 4-2) keyword search, and by target sequence similarity 
(Figure 4-3) and drug tanimoto similarity search (Figure 4-4). Full TTD data 
download is also provided. Two optional whole database searches are 
provided: one is to search by target name, and another is by drug name. 
Different whole database search options will list search results in different 
manners, which is designed to facilitate users with different initial searching 
information. Customized search fields include target name, drug name, disease 
indication, target biochemical class, drug mode of action, and drug therapeutic 
class. In current TTD, 112 disease indications, 61 target biochemical classes, 
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20 drug mode of actions, and 157 drug therapeutic classes are available for 
customized selection. 
 
Figure 4-1 Home page of TTD 2010 
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Figure 4-2 Customized search page of TTD 2010 
 
Figure 4-3 Sequence similarity search page of TTD 2010 




Figure 4-4 Drug tanimoto similarity search page of TTD 2010 
 
After input keywords and search in TTD database, the intermediate searching 
results will be displayed for user to choose from. For example, “VEGFR” was 
used into the search box–“List search results by targets” at the home page. The 
intermediate search results page (Figure 4-5) will display Vascular endothelial 
growth factor receptor 1, Vascular endothelial growth factor receptor 2, 
Vascular endothelial growth factor receptor 3 and mRNA of VEGFR1 for 
users to make further selection. 
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Figure 4-5 Targets list page of “VEGFR” 
 
Target detail information page (Figure 4-6) lists target name, target status 
(successful, clinical trial and research), synonyms, disease, corresponding 
drugs, target bio-chemical class, pathway involved, target uniprot accession 
number, PDB structure, protein function, sequence information, US patents, 
drug mode of action, references, and so on. Moreover, further information 
about each target can be accessed via crosslink to external databases, like 
SwissProt/UniProt, PDB, KEGG, OMID, and Brenda database. 
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Figure 4-6 TTD target detail information page 
  92 
 
Drug detail information page (Figure 4-7) lists drug name, drug synonyms, 
trade name, company information, disease indication, 3D drug structure 
displayed, 2D&3D structural MOL files for download, target therapeutic class, 
CAS number, formula, PubChem ID, ChEBI ID, SuperDrug ATC & CAS IDs, 
primary therapeutic target(s), references, and so on. Furthermore, further drug 
information can be accessed via cross links to the external databases, such as 




Figure 4-7 TTD drug detail information page 
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Related target or drug entries can be recursively searched by clicking a disease 
or drug name. Similarity targets of an input protein sequence in FASTA 
format can be searched by using the NCBI BLAST sequence alignment tool 
[250]. Similarity drugs of an input drug structure can be searched by using 
molecular descriptor based tanimoto similarity searching method[251, 252]. 
Target and drug entries are assigned standardized TTD IDs for easy 
identification, analysis and linkage to other related databases. The whole TTD 
data, target sequences along with Swissprot and Entrez gene IDs, and drug 
structures can be downloaded via the download link. A separate downloadable 
file contains the list of TTD drug ID, drug name and the corresponding IDs in 
other cross-matching database PubChem, DrugBank, SuperDrug, and ChEBI. 
The corresponding HGNC name and Swissprot and Entrez gene ID of each 
target is provided in the target page. The SMILES and InCHI of each drug is 
provided in the drug page. 
4.4 Target and drug similarity searching 
Target similarity search is based on BLAST [250] algorithm to determine the 
similarity level between the sequence of an input protein and the sequence of 
each of the TTD target entries. The NCBI website 
(ftp://ftp.ncbi.nlm.nih.gov/blast/executables/release/) is used for downloading 
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BLAST program. The result of similarity targets searched out are ranked by 
E-value and BLAST score [250]. E-value has been reported to give reliable 
predictions of the homologous relationships [253] and a cutoff of 0.001 can be 
used to find 16% more structural relationships in the SCOP database than 
when using a standard sequence similarity with a 40% sequence-identity 
threshold[254]. The majority of protein pairs sharing ~50% (or higher) 
sequence-identity differ by < 1 Å RMS deviation[255, 256]. A larger 
structural deviation alters drug-binding properties probably. 
Drug similarity search is based on the tanimoto similarity search method 
[251]. An input compound structure in MOL or SDF format is converted into a 
vector composed of molecular descriptor by using MODEL[161]. These 
molecular descriptors are quantitative representations of structural and 
physicochemical features of molecules, which have been extensively used in 
deriving structure-activity relationships, quantitative structure-activity 
relationship and virtual screening tool for drug discovery[146, 202]. Based on 
the results of our earlier studies[47], a total of 98 1D and 2D descriptors were 
used as the components of the compound vector, which include 18 descriptors 
in the class of simple molecular property, 3 descriptors in chemical property, 
35 descriptors in molecular connectivity and shape, and 42 descriptors in 
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electro-topological state. The vector of an input compound i is then compared 
to drug j in TTD by using the Tanimoto coefficient sim(i,j)[251]: 
 
where l is the total number of molecular descriptors. Tanimoto coefficient of 
similarity compounds are typically in the range of 0.8 to 0.9[185, 186]. Hence 
compound i is considered to be very similar, similar, moderately similar, or 
un-similar to drug j if  sim(i,j) > 0.9, 0.85< sim(i,j) <0.9, 0.75< sim(i,j) <0.85, 
or sim(i,j) > 0.75 respectively. 
In conclusion, TTD 2010 update is intended to be a more useful resource in 
complement to other related databases by providing comprehensive 
information to the primary targets and other drug data for the approved, 
clinical trial, and experimental drugs. In addition to the continuous update of 
new target and drug information, efforts will be devoted to the incorporation 
of more features into TTD. Increasing amounts of data about the genomic, 
proteomic, structural, functional and systems profiles of therapeutic targets 
have been and are being generated[230-236]. Apart from establishing 
crosslink to the emerging sources, some of the profiles extracted or derived 
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has been used for developing target discovery methods[241-243], some of 
these methods may be included in TTD in addition to the BLAST tool for 
similarity target searching. As in the case of PDTD[246], some of the virtual 
screening methods and datasets may also be included in TTD for facilitating 
target oriented drug lead discovery. 
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Chapter 5 Development and experimental test of 
support vector machines virtual screening method for 
searching Src inhibitors from large compound libraries  
 
5.1 Introduction 
Src promotes tumour invasion and metastasis, facilitates VEGF-mediated 
angiogenesis and survival in endothelial cells, and enhances growth factor 
driven proliferation in fibroblasts [257]. Src is known to modulate cell 
proliferation and cancers through several signaling pathways such as STAT3 
pathway, the PI3K pathway and the MAPK pathway [258]. Src consists of 6 
functional domain: homology domain 4 (SH4), unique domain, homology 
domain (SH3), homology domain (SH2), catalytic domain (SH1), and 
C-terminal regulatory tail [259]. Src activation can be altered by many 
different cell processes through upstream kinases or phosphatases. Src 
associated pathway, its structure and activity regulation [260] have 
been explored. 
 
Src is one of the multiple kinase targets of a number of multi-target kinase 
inhibitors effective in the clinical treatment of leukemia and in clinical trials of 
other cancers [261-263]. The successes and problems of these inhibitors have 
raised significant interest and efforts in discovering new Src inhibitors 
[264-266]. Several in-silico methods have been used for facilitating the search 
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and design of Src inhibitors, which include pharmacophore [267], Quantitative 
Structure Activity Relationship (QSAR) [268], and molecular docking [265]. 
 
While these in-silico methods have shown impressive capability in the 
identification of potential Src inhibitors, their applications may be affected by 
such problems as the vastness and sparse nature of chemical space needing to 
be searched, complexity and flexibility of target structures, difficulties in 
accurately estimating binding affinity and solvation effects on molecular 
binding, and limited representativeness of training active compounds [69, 269, 
270]. It is desirable to explore other in-silico methods that complement these 
methods by expanded coverage of chemical space, increased screening speed, 
and reduced false-hit rates without necessarily relying on the modelling of 
target structural flexibility, binding affinity and salvation effects.  
 
Support vector machines (SVM) has recently been explored as a promising 
ligand-based virtual screening (VS) method that produces high yields and low 
false-hit rates in searching active agents of single and multiple mechanisms 
from large compound libraries [114] and in identifying active agents of 
diverse structures [114, 171-174]. Good VS performance can also be achieved 
by SVM trained from sparsely distributed active compounds [252]. SVM 
classifies active compounds based on the separation of active and inactive 
compounds in a hyperspace constructed by their physicochemical properties 
rather than structural similarity to active compounds per se, which has the 
advantage of not relying on the accurate computation of structural flexibility, 
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activity-related features, binding affinity and solvation effects. Moreover, the 
fast speed of SVM enables efficient search of vast chemical space. Therefore, 
SVM may be a potentially useful VS tool to complement other in-silico 
methods for searching Src inhibitors from large libraries. 
 
In this work, we developed a SVM VS model for identifying Src inhibitors, 
and evaluated its performance by both 5-fold cross validation test and large 
compound database screening test. In 5-fold cross validation test, a dataset of 
Src inhibitors and non-inhibitors was randomly divided into 5 groups of 
approximately equal size, with 4 groups used for training a SVM VS tool and 
1 group used for testing it, and the test process is repeated for all 5 possible 
compositions to derive an average VS performance. In large database 
screening test, a SVM VS tool was developed by using Src inhibitors 
published before 2011, its yield (percent of known inhibitors identified as 
virtual-hits) was estimated by using Src inhibitors reported since 2011 and not 
included in the training datasets, virtual-hit rate and false-hit rate in searching 
large libraries were evaluated by using 13.56M PubChem and 168K MDDR 
compounds, and an additional set of 9,305 MDDR compounds similar in 
structural and physicochemical properties to the known Src inhibitors.  
 
Moreover, VS performance of SVM was compared to those of two 
similarity-based VS methods, Tanimoto similarity searching and k nearest 
neighbour (kNN), and an alternative but equally popularly used machine 
learning method, probabilistic neural network (PNN) method, based on the 
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same training and testing datasets (same sets of PubChem and MDDR 
compounds) and molecular descriptors. In a study that compares the 
performance of SVM to 16 classification methods and 9 regression methods, it 
has been reported that SVMs shows mostly good performances both on 
classification and regression tasks, but other methods proved to be very 
competitive [271]. Therefore, it is useful to evaluate the VS performance of 
SVM in searching large compound libraries by comparison with those of both 
similarity-based approaches and other typical machine learning method. 
 
PubChem and MDDR contain high percentages of inactive compounds 
significantly different from the known Src inhibitors, and the easily 
distinguishable features may make VS enrichments artificially good [272]. 
Therefore, VS performance may be more strictly tested by using subsets of 
compounds that resemble the physicochemical properties of the known Src 
inhibitors so that enrichment is not simply a separation of trivial 
physicochemical features [186]. To further evaluate whether our SVM VS tool 
predict Src inhibitors and non-inhibitors rather than membership of certain 
compound families, distribution of the predicted active and inactive 
compounds in the compound families were analyzed. 
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5.2 Materials and methods 
5.2.1 Compound collections and construction of training and 
testing datasets 
 
We collected 1,703 Src inhibitors reported before 2011, with IC50<10µM, 
from the literatures [273-277] and the BindingDB database [161]. The 
inhibitor selection criterion of IC50<10µM was used because it covers most of 
the reported HTS and VS hits [278, 279]. The structures of representative Src 
inhibitors are shown in Figure 5-1. As few non-inhibitors have been reported, 
putative non-inhibitors were generated by using our method for generating 
putative inactive compounds [246, 252]. This method requires no knowledge 
of known inactive compounds and active compounds of other target classes, 
which enables more expanded coverage of the “non-inhibitor” chemical space. 
Although the yet-to-be-discovered inhibitors are likely distributed in some of 
these “non-inhibitor” families, a substantial percentage of these inhibitors are 
expected to be identified as inhibitors rather than non-inhibitors even-though 
representatives of their families are putatively assigned as non-inhibitors 
[246]. 13.56M PubChem and 168K MDDR compounds were grouped into 
8,423 compound families by clustering them in the chemical space defined by 
their molecular descriptors [193, 194]. The number of generated families is 
consistent with the 12,800 compound-occupying neurons (regions of 
topologically close structures) for 26.4 million compounds of up to 11 atoms 
[65], and the 2,851 clusters for 171,045 natural products [196].  
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Figure 5-1 The structures of representative c-Src inhibitors. Comppound 1:SKI-606 
IC50=0.25µm [144]; Compound 2: AG-1879, IC50=0.085µm; Compound 3: Sunitinib, SU 
11248, IC50=1µm [282]; Compound 4: IC50=0.5µm [280]; Compound 5: IC50=0.26µm 
[281]; Compound 6: IC50=0.001µm [282]. 
 
Our collected Src inhibitors are distributed in 493 families. Because of the 
extensive efforts in searching kinase inhibitors from known compound 
libraries, the number of undiscovered Src inhibitor families in PubChem and 
  103 
MDDR databases is expected to be relatively small, most likely no more than 
several hundred families. The ratio of the discovered and undiscovered 
inhibitor families (hundreds) and the families that contain no known Src 
inhibitor (8,423 based on the current versions of PubChem and MDDR) is 
expected to be <15%. Therefore, putative non-inhibitor training dataset can be 
generated by extracting a few representative compounds from each of those 
families that contain no known inhibitor, with a maximum possible “wrong” 
classification rate of <15% even when all of the undiscovered inhibitors are 
misplaced into the non-inhibitor class. The noise level generated by up to 15% 
“wrong” negative family representation is expected to be substantially smaller 
than the maximum 50% false-negative noise level tolerated by SVM [172]. 
Based on earlier studies [246, 252] and this work, it is expected that a 
substantial percentage of the un-discovered inhibitors in the putative 
“non-inhibitor” families can be classified as inhibitor despite their family 
representatives are placed into the non-inhibitor training sets.  
 
In the database screening test, 60.1% of the families that contain Src inhibitors 
reported since 2011 [283-288] are not covered by the Src inhibitor training 
dataset (inhibitors reported before 2011). The representative compounds of 
these families, none of which happen to be Src inhibitor, were deliberately 
placed into the inactive training sets because the inhibitors in these families 
are not supposed to be known in our study. As shown in earlier studies [246, 
252] and in this work, a substantial percentage of the inhibitors in these 
misplaced inhibitor-containing “non-inhibitor” families were predicted as 
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inhibitors by our SVM VS tool. Moreover, a small percentage of the 
compounds in these putative non-inhibitor datasets are expected to be 
un-reported and un-discovered inhibitors, their presence in these datasets is 
not expected to significantly affect the estimated false hit rate of SVM.  
 
5.3 Results and discussion 
5.3.1 Performance of SVM, kNN and PNN identification of 
Src inhibitors based on 5-fold cross validation test 
 
The parameters of our SVM, kNN and PNN models were determined by 
5-fold cross-validation studies of Src inhibitors and non-inhibitors. The results 
of these tests for SVM, kNN and PNN are shown in Tables 5-1, 5-2, 5–3 and 
Figure 5-2 respectively. Overall, the sensitivity of SVM, k-NN and PNN is in 
the range of 93.53%~95.01%, 88.56%~92.94% and 93.53%~97.06%, the 
specificity in the range of 99.81%~99.90%, 99.57%~99.77% and 
97.76%~98.03%, and overall accuracy Q in the range of 99.67%~99.76%, 
99.35%~99.48% and 97.69%~97.91% respectively. The inhibitor accuracies 
of our SVM are comparable to or slightly better than the reported accuracies 
of 58.3%~67.3% for protein kinase C inhibitors by SVM-RBF and CKD 
methods [192], 83% for Lck inhibitors by SVM method [289], and 74%~87% 
for inhibitors of any of the 8 kinases (3 Ser/Thr and 5 Tyr kinases) by SVM, 
ANN, GA/kNN, and RP methods [290]. The non-inhibitor accuracies are 
comparable to the value of 99.9% for Lck inhibitors [289] and substantially 
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better than the typical values of 77%~96% of other studies [192, 290]. Caution 
needs to be exercised about straightforward comparison of these results, which 
might be misleading because the outcome of VS strongly depends on the 
datasets and molecular descriptors used. Based on these rough comparisons, 
SVM appears to show good capability in identifying Src inhibitors at low 
false-hit rates.  
 
Table 5-1 Performance of SVM for identifying Src inhibitors and non-inhibitors evaluated by 
5-fold cross validation study 
Cross 
-Validation 

















TN FP SP 
 
  
1 1362/341 320 21 93.84% 50654/12664 12651 13 99.90% 99.74% 0.948 
2 1362/341 324 17 95.01% 50654/12664 12650 14 99.89% 99.76% 0.953 
3 1362/341 324 17 95.01% 50654/12664 12640 24 99.81% 99.68% 0.939 
4 1363/340 318 22 93.53% 50655/12663 12642 21 99.83% 99.67% 0.935 
5 1363/340 322 18 94.71% 50655/12663 12643 20 99.84% 99.71% 0.943 
Average    94.42%    99.85% 99.71% 0.944 
Std Dev    0.0069    0.0004 0.0004 0.0072 
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Table 5-2 Performance of kNN for identifying Src inhibitors and non-inhibitors evaluated by 
















TN FP SP   
1 1362/341 302 39 88.56% 50654/12664 12635 29 99.77% 99.48% 0.896 
2 1362/341 313 28 91.79% 50654/12664 12620 44 99.65% 99.45% 0.894 
3 1362/341 311 30 91.20% 50654/12664 12610 54 99.57% 99.35% 0.878 
4 1363/340 316 24 92.94% 50655/12663 12619 44 99.65% 99.48% 0.901 
5 1363/340 302 38 88.82% 50655/12663 12632 31 99.76% 99.47% 0.895 
Average    90.66%    99.68% 99.44% 0.893 
Std Dev    0.0191    0.0008 0.0005 0.0085 
Std Err    0.0085    0.0004 0.0002 0.0038 
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Table 5-3 Performance of PNN for identifying Src inhibitors and non-inhibitors evaluated by 5-fold 
















TN FP SP   
1 1362/341 319 22 93.55% 50654/12664 12413 251 98.02% 97.90% 0.715 
2 1362/341 324 17 95.01% 50654/12664 12380 284 97.76% 97.69% 0.702 
3 1362/341 330 11 96.77% 50654/12664 12395 269 97.88% 97.85% 0.722 
4 1363/340 330 10 97.06% 50655/12663 12389 274 97.84% 97.82% 0.720 
5 1363/340 318 22 93.53% 50655/12663 12413 250 98.03% 97.91% 0.715 
Average    95.19%    97.90% 97.83% 0.715 
Std Dev    0.0169    0.0012 0.0009 0.0075 
Std Err    0.0076    0.0005 0.0004 0.0034 
 
 
  108 
 
Figure 5-2 The 5-fold cross-validation studies of Src inhibitors across methods with the averaged 
sensitivity together with their respective error bars. 
 
5.3.2 Virtual screening performance of SVM in searching Src 
inhibitors from large compound libraries  
As outlined in the methods section, we developed a SVM VS tool for searching Src 
inhibitors from large were developed by using Src kinases reported before 2011. The 
VS performance of SVM in identifying Src inhibitors reported since 2011 and in 
searching MDDR and PubChem databases is summarised in Table 5-4. The yield in 
searching Src inhibitors reported since 2011 is 70.45%, which is comparable to the 
reported 50%~94% yields of various VS tools [291]. Strictly speaking, direct 
comparison of the reported performances of these VS tools is inappropriate because of 
the differences in the type, composition and diversity of compounds screened, and in 
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the molecular descriptors, VS tools and their parameters used. The comparison cannot 
go beyond the statistics of accuracies. 
 
Table 5-4 Virtual screening performance of support vector machines for identifying Src inhibitors from 
large compound libraries 
 
Inhibitors in Training 
Set 
Number of Inhibitors 1703 
Number of Chemical Families Covered by Inhibitors 493 
Inhibitors in Testing 
Set 
Number of Inhibitors 44 
Number of Chemical Families Covered by Inhibitors 35 






Number and Percent of Identified True Inhibitors Outside Training 
Chemical Families 
15(34.1%) 








Number and Percent of the 9,305 MDDR Compounds Similar to the 
Known Inhibitors Identified as Inhibitors 
719 (7.73%) 
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We also evaluated virtual-hit rates and false-hit rates of SVM in screening compounds 
that resemble the structural and physicochemical properties of the known Src 
inhibitors by using 9,305 MDDR compounds similar to an Src inhibitor in the training 
dataset. Similarity was defined by Tanimoto similarity coefficient ≥  0.9 between a 
MDDR compound and its closest inhibitor [252]. This stricter similarity metric was 
used for conducting a stricter test of our SVM model. SVM identified 719 virtual-hits 
from these 9,305 MDDR similarity compounds (virtual-hit rate 7.73%), which 
suggests that SVM has some level of capability in distinguishing Src inhibitors from 
non-inhibitor similarity compounds. Significantly lower virtual-hit rates and thus 
false-hit rates were found in screening large libraries of 168K MDDR and 13.56M 
PubChem compounds. The numbers of virtual-hits and virtual-hit rates in screening 
168K MDDR compounds are 1,496 and 0.89% respectively. The numbers of 
virtual-hits and virtual-hit rates in screening 13.56M PubChem compounds are 44,843 
and 0.33% respectively.  
 
Substantial percentages of the MDDR virtual-hits belong to the classes of 
antineoplastic, tyrosine-specific protein kinase inhibitors, signal transduction 
inhibitors, antiangiogenic, and antiarthritic (Table 5-5, details in next section). As 
some of these virtual-hits may be true Src inhibitors, the false-hit rate of our SVM is 
at most equal to and likely less than the virtual-hit rate. Hence the false-hit rate is 
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<7.73% in screening 9,305 MDDR similarity compounds, <0.89% in screening 168K 
MDDR compounds, and <0.33% in screening 13.56M PubChem compounds, which 
are comparable and in some cases better than the reported false-hit rates of 
0.0054%~8.3% of SVM [246, 252], 0.08%~3% of structure-based methods, 
0.1%~5% by other machine learning methods, 0.16%~8.2% by clustering methods, 
and 1.15%~26% by pharmacophore models [291]. 
5.3.3 Experimental test of a SVM identified virtual-hit 
Three virtual hits of the same novel scaffold from in-house libraries not found in the 
known the Src inhibitor were evaluated for inhibitory activity against Src. Src kinase 
was incubated with substrates, compounds and ATP in a final buffer of 25mM 
HEPES (pH 7.4), 10mM MgCl2, 0.01% Triton X-100, 100µg/mL BSA, 2.5mM DTT 
in 384-well plate with the total volume of 10µl. The assay plate was incubated at 30℃ 
for 1h and stopped with the addition of equal volume of kinase glo plus reagent. The 
luminescence was read at envision. The signal was correlated with the amount of ATP 
present in the reaction and was inversely correlated with the kinase activity. One of 
three virtual hits showing in Figure 5-3 was found to inhibit Src at a moderate rate of 
4.85% at 20µM. 
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Figure 5-3 Virtual hit inhibiting Src at a moderate rate of 4.85% at 20µM 
 
5.3.4 Evaluation of SVM identified MDDR virtual-hits 
SVM identified MDDR virtual-hits were evaluated based on the known biological or 
therapeutic target classes specified in MDDR. Table 5-5 gives the MDDR classes that 
contain higher percentage (≥3%) of SVM virtual -hits and the percentage values. We 
found that 623 (41.6%) of the 1,496 virtual-hits belong to the antineoplastic class, 
which represent 2.9% of the 21,557 MDDR compounds in the class. In particular, 231 
(15.4%) of the virtual-hits belong to the tyrosine-specific protein kinase inhibitor 
class, which represent 19.6% of the 1,181 MDDR compounds in the class. Moreover, 
194 (13.0%) and 75 (5.0%) of the virtual-hits belong to the signal transduction 
inhibitor and antiangiogenic classes, representing 9.5% and 4.6% of the 2,037 and 
1,629 members in these classes respectively. Therefore, many of the SVM virtual-hits 
are antineoplastic compounds that inhibit tyrosine kinases and possibly other kinases 
involved in signal transduction and angiogensis pathways. While some of these kinase 
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inhibitors might be true Src inhibitors, a significant percentage of them are expected 
to arise from false selection of inhibitors of other kinases.  
 
Table 5-5 MDDR classes that contain higher percentage (≥3%) of SVM virtual -hits and the percentage 
values. Virtual-hits are identified by SVMs in screening 168K MDDR compounds for Src inhibitors. 
The total number of SVM identified virtual hits is 1,496. 
 
MDDR Classes that Contain Higher Percentage 
(≥3%) of Virtual Hits 
No of Virtual 
Hits in Class 
Percentage of Class Members 
Selected as Virtual Hits 
Antineoplastic 623 2.9% 
Tyrosine-Specific Protein Kinase Inhibitor 231 19.6% 
Signal Transduction Inhibitor 194 9.5% 
Antiarthritic 176 1.5% 
Antiallergic/Antiasthmatic 83 0.8% 
Antihypertensive 76 0.7% 
Antiangiogenic 75 4.6% 
Treatment for Osteoporosis 55 2.2% 
Antidepressant 49 0.8% 
 
A total of 176 (11.8%) SVM virtual-hits belong to the antiarthritic class. A primary 
feature of rheumatoid arthritis in synovial tissues is the abnormal stimulation of fibrin 
deposition, angiogenesis and proinflammatory processes, which are promoted by 
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thrombin increased IL-6 production via the PAR1 receptor/PI-PLC/PKC 
alpha/c-Src/NF-kappaB and p300 signaling pathways [292]. Therefore, Src inhibitors 
may have some effects against arthritis via interference with some of these processes. 
Moreover, several other kinases have been implicated in arthritis. An Abl inhibitor 
Gleevec has been reported to be effective in treatment of arthritis, which is probably 
due to its inhibition of other related kinases such as c-kit and PDGFR [293]. 
EGFR-like receptor stimulates synovial cells and its elevated activities may be 
involved in the pathogenesis of rheumatoid arthritis [294]. VEGF has been related to 
such autoimmune diseases as systemic lupus erythematosus, rheumatoid arthritis, and 
multiple sclerosis [295]. FGFR may partly mediates osteoarthritis [296]. PDGF-like 
factors stimulates the proliferative and invasive phenotype of rheumatoid arthritis 
synovial connective tissue cells [297]. Lck inhibition leads to immunosuppression and 
has been explored for the treatment of rheumatoid arthritis and asthma [298]. 
Therefore, some of the SVM virtual-hits in the antiarthritic class may be inhibitors of 
these kinases or their kinase-likes capable of producing antiarthritic activities.  
 
Moreover, 83 (5.5%), 76 (5.1%), 55 (3.7%) and 49 (3.3%) of the SVM virtual hits are 
in the antiallergic/antiasthmatic, antihypertensive, osteoporosis treatment and 
antidepressant classes respectively. Src or Src family kinases have been implicated in 
and the respective inhibitors have shown observable effects against these diseases. For 
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instance, Src family kinases and lipid mediators have been found to partly control 
allergic inflammation [299]. Inhibition of Src family kinase-dependent signaling 
cascades in mast cells may exert anti-allergic activity [300]. Up-regulation of Src 
signaling has been suggested to be important in the profibrotic and proinflammatory 
actions of aldosterone in a genetic model of hypertension, which can be significantly 
reduced by mineralocorticoid receptor blocker and Src inhibitor [301]. Src signalling 
pathways play critical roles in osteoclasts and osteoblasts, and Src inhibitors have 
been developed as therapeutic agents for bone diseases [302, 303]. Src-family protein 
tyrosine kinases negatively regulate cerebellar long-term depression, which can be 
recovered by the application of Src-family protein tyrosine kinase inhibitors [304]. 
Therefore, some of the SVM virtual hits in these four MDDR classes may be Src 
inhibitors or Src family kinase inhibitors capable of regulating allergic inflammation, 
hypertension, osteoporosis and depression respectively. 
 
5.3.5 Comparison of virtual screening performance of SVM with 
those of other vrtual screening methods 
To evaluate the level of performance of SVM and whether the performance is due to 
the SVM classification models or to the molecular descriptors used, SVM results were 
compared with those of three other VS methods based on the same molecular 
descriptors, training dataset of Src inhibitors reported before 2011, and the testing 
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dataset of Src inhibitors reported since 2011 and 168K MDDR compounds. The three 
other VS methods include two similarity-based methods, Tanimoto-based similarity 
searching and kNN methods, and an alternative machine learning method PNN. As 
shown in Table 5-6, the yield and maximum possible false-hit rate of the 
Tanimoto-based similarity searching, kNN and PNN methods are 36.84%  and 
5.54%, 38.64% and 2.49%, and 50.00% and 2.60% respectively. Compared to these 
results, the yield of SVM is better than these similarity-based VS method, and the 
false-hit rate of SVM is significantly reduced by 6.22, 2.80, and 2.92 fold 
respectively. These suggests that SVM performance is due primarily to the SVM 
classification models rather than the molecular descriptors used, and SVM is capable 
of achieving comparable yield at substantially reduced false-hit rate as compared to 
both similarity-based approach and alternative machine learning method. Our results 
are consistent with the report that SVM shows mostly good performances both on 
classification and regression tasks, but other classification and regression methods 
proved to be very competitive [271]. 
  117 
Table 5-6 Comparison of virtual screening performance of SVM with those of other methods 
Method Inhibitors in Training Set Inhibitors in Testing Set Virtual Screening Performance  





















Yield  No and Percent 





No and Percent of 




No and Percent of 
the 9,305 MDDR 
Compounds Similar 
to the Known 
Inhibitors Identified 
as Virtual Inhibitors 
Support Vector 
Machines 
1703 493 44 35 51.43% 
70.45% 15(34.1%) 1,496 (0.89%) 719 (7.73%) 
Tanimoto 
Similarity 
36.84% 9(20.5%) 9,305 (5.54%) 9,305 (100%) 
K Nearest 
Neighbour 
38.64% 10(22.7%) 4,182 (2.49%) 1,169 (12.57%) 
Probabilistic 
Neural Network 
50.0% 13(29.5%) 4,386 (2.60%) 1,184 (12.72%) 
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5.3.6 Does SVM select Src inhibitors or membership of compound 
families? 
To further evaluate whether SVM identifies Src inhibitors rather than membership of 
certain compound families, compound family distribution of the identified Src 
inhibitors and non-inhibitors were analyzed. 34.1% of the identified inhibitors belong 
to the families that contain no known Src inhibitors. For those families that contain at 
least one known Src inhibitor, >70% of the compounds (>90% in majority cases) in 
each of these families were predicted as non-inhibitor by SVM. These results suggest 
that SVM identify Src inhibitors rather than membership to certain compound 
families. Some of the identified inhibitors not in the family of known inhibitors may 
serve as potential “novel” Src inhibitors. Therefore, as in the case shown by earlier 
studies [114], SVM has certain capacity for identifying novel active compounds from 
sparse as well as regular-sized active datasets. 
 
5.4 Conclusions 
Our study suggested that SVM is capable of identifying Src inhibitors at comparable 
yield and in many cases substantially lower false-hit rate than those of typical VS 
tools reported in the literatures. It can be used for searching large compound libraries 
at sizes comparable to the 13.56M PubChem and 168K MDDR compounds at low 
false-hit rates. The performance of SVM is substantially improved against several 
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other VS method based on the same datasets and molecular descriptors, suggesting 
that the VS performance of SVM is primarily due to SVM classification models rather 
than the molecular descriptors used. Three SVM virtual hits of the same novel 
scaffold were experimentally tested, one of which showed moderate Src inhibition 
rate. Because of its high computing speed and generalization capability for covering 
highly diverse spectrum compounds, SVM can be potentially explored to develop 
useful VS tools to complement other VS methods or to be used as part of integrated 
VS tools in facilitating the discovery of Src inhibitors and other active compounds 
[305-307]. 
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Chapter 6 Support vector machines virtual screening of 
VEGFR-2 Inhibitors from large compound libraries: model 
development and experimental test 
 
6.1 Background 
VEGFR regulates angiogenesis, growth, migration and survival [308]. There are 3 main 
VEGFR subtypes, VEGFR-2 mediates almost all of the known cellular responses to VEGF, 
VEGFR-1 modulates VEGFR-2 signaling and acts as a dummy/decoy receptor, and 
VEGFR-3 mediates lymphangiogenesis in response to VEGF-C and VEGF-D [308]. 
VEGFR inhibitors have been successfully used for cancer treatments [261, 309]. While 
increasing number of VEGFR inhibitors have been developed and tested, several problems 
limit the scope of their practical applications. These problems include increased toxicity 
partly due to the targeting of multiple kinases, acquired resistances, and reduced tumor 
responses (VEGFR inhibitors can cause extensive tumor necrosis without a marked 
decrease in tumor size) [310]. Moreover, on-target toxicity against specific VEGFR 
subtypes in various tissues is also a significant problem for the applications of VEGFR 
inhibitors [311]. The successes of VEGFR inhibitors and the encountered problems have 
led to further efforts for discovering new inhibitors [261, 309]. 
 
In-silico methods such as pharmacophore [312], QSAR [313-315], fragment-based method 
[316], molecular docking [317, 318], and their combinations [312, 315] have been used for 
facilitating the search and design of VEGFR inhibitors, which have shown impressive 
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capability in the identification of potential VEGFR inhibitors, but their applications may be 
affected by such problems as the vastness and sparse nature of chemical space needing to 
be searched, complexity and flexibility of target structures, difficulties in accurately 
estimating binding affinity and solvation effects on molecular binding, and limited 
representativeness of training active compounds [69, 269, 270]. Therefore, it is desirable to 
explore other in-silico methods that complement these methods by expanded coverage of 
chemical space, increased screening speed, and reduced false-hit rates without necessarily 
relying on the modelling of target structural flexibility, binding affinity and salvation 
effects.  
 
Support vector machines (SVM) has been explored as such a VS method capable of 
producing high yields and low false-hit rates in searching active agents of single and 
multiple mechanisms from large compound libraries [319] and in identifying active agents 
of diverse structures [171-174, 319]. Good VS performance can also be achieved by SVM 
trained from sparsely distributed active compounds [252]. SVM classifies active 
compounds based on the separation of active and inactive compounds in a hyperspace 
constructed by their physicochemical properties rather than structural similarity to active 
compounds per se, which has the advantage of not necessarily relying on the modeling of 
target structural flexibility and the computation of activity-related features, binding affinity 
and solvation effects. Moreover, the fast speed of SVM enables efficient search of vast 
chemical space. Therefore, SVM may be a potentially useful VS tool to complement other 
in-silico methods for searching VEGFR inhibitors from large libraries. 
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In this work, SVM was tested for its capability in searching VEGFR-2 inhibitors from large 
compound libraries. Our focus on inhibitors of VEGFR-2 subtype was based on the 
availability of reported inhibitors of the subtype and the consideration that VEGFR-2 
mediates almost all of the known cellular responses to VEGF [308]. The performance of 
SVM was evaluated by both 5-fold cross validation test and large database screening test. 
In 5-fold cross validation test, VEGFR-2 inhibitors and non-inhibitors was randomly 
divided into 5 groups of approximately equal size, with 4 groups used for training a SVM 
VS tool and 1 group used for testing it, and the test process is repeated for all 5 possible 
compositions to derive an average VS performance. In large database screening test, SVM 
was developed by using VEGFR-2 inhibitors published before 2012, its yield (percent of 
known inhibitors identified as virtual-hits) was estimated by using VEGFR-2 inhibitors 
reported since 2012 and not included in the training datasets, virtual-hit rate and false-hit 
rate of the SVM in searching large libraries were evaluated by using 13.56M PubChem, and 
168K MDDR, and an additional set of 13,872 MDDR compounds similar in structural and 
physicochemical properties to the known VEGFR-2 inhibitors.  
 
Moreover, VS performance of SVM was compared to those of two similarity-based VS 
methods, Tanimoto similarity searching and k nearest neighbour (kNN), and an alternative 
but equally popularly used machine learning method, probabilistic neural network (PNN) 
method, based on the same training and testing datasets (same sets of PubChem and MDDR 
compounds) and molecular descriptors. In a study that compares the performance of SVM 
to 16 classification methods and 9 regression methods, it has been reported that SVMs 
shows mostly good performances both on classification and regression tasks, but other 
methods proved to be very competitive [271]. Therefore, it is useful to evaluate the VS 
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performance of SVM in searching large compound libraries by comparison with those of 
both similarity-based approaches and other typical machine learning method. 
 
Databases such as PubChem and MDDR contain high percentages of inactive compounds 
significantly different from VEGFR-2 inhibitors, and the easily distinguishable features 
may make VS enrichments artificially good [272]. Therefore, VS performance may be 
more strictly tested by using subsets of compounds that resemble the physicochemical 
properties of the known VEGFR-2 inhibitors so that enrichment is not simply a separation 
of trivial physicochemical features [186]. To further evaluate whether SVM predict 
VEGFR-2 inhibitors and non-inhibitors rather than membership of certain compound 
families, distribution of the predicted active and inactive compounds in the compound 
families were analyzed. Moreover, VS performance of SVM for screening MDDR 
compounds was compared with that of Tanimoto similarity search method on the same 
molecular descriptors, training dataset to determine whether the performance of SVM is 
due to the SVM classification models or to the molecular descriptors used. 
 
6.2 Materials and methods 
6.2.1 Compound collections and construction of training and testing 
datasets 
Using the inhibitor selection criterion of IC50<10µM, which covers most of the reported 
HTS and VS hits [278, 279], we collected 3,653 VEGFR-2 inhibitors regardless of their 
activities against other VEGFR subtypes from the literature reported before 2012 [319-334] 
and the BindingDB database [161]. The structures of representative VEGFR-2 inhibitors 
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are shown in Figure 6-1. As few non-inhibitors have been reported, putative non-inhibitors 
were generated by using our method for generating putative inactive compounds [246, 
252]. This method requires no knowledge of known inactive compounds and active 
compounds of other target classes, which enables more expanded coverage of the 
“non-inhibitor” chemical space. Although the yet-to-be-discovered inhibitors are likely 
distributed in some of these “non-inhibitor” families, a substantial percentage of these 
inhibitors are expected to be identified as inhibitors rather than non-inhibitors even-though 
representatives of their families are putatively assigned as non-inhibitors [246]. 13.56M 
PubChem and 168K MDDR compounds were grouped into 8,423 compound families by 
clustering them in the chemical space defined by their molecular descriptors [193, 194]. 
The number of generated families is consistent with the 12,800 compound-occupying 
neurons (regions of topologically close structures) for 26.4 million compounds of up to 11 

















































Figure 6-1 The structures of representative VEGFR-2 inhibitors. Compound 1: Sunitinib,IC50=0.009µm,; 
Compound 2:IC50=0.032µm [335]; Compound 3:Vatalanb (PTK787), IC50=0.037µm; Compound 4: 
IC50=0.012µm [336]; Compound 5: IC50=0.004 µm [337]; Compound 6:IC50=0.111µm[338]. 
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Our collected VEGFR-2 inhibitors are distributed in 845 families. Because of the extensive 
efforts in searching kinase inhibitors from known compound libraries, the number of 
undiscovered VEGFR-2 inhibitor families in PubChem and MDDR databases is expected 
to be relatively small, most likely no more than several hundred families. The ratio of the 
discovered and undiscovered inhibitor families (hundreds) and the families that contain no 
known inhibitor of each kinase (8,423 based on the current versions of PubChem and 
MDDR) is expected to be <15%. Therefore, putative non-inhibitor training dataset can be 
generated by extracting a few representative compounds from each of those families that 
contain no known inhibitor, with a maximum possible “wrong” classification rate of <15% 
even when all of the undiscovered inhibitors are misplaced into the non-inhibitor class. The 
noise level generated by up to 15% “wrong” negative family representation is expected to 
be substantially smaller than the maximum 50% false-negative noise level tolerated by 
SVM [172]. Based on earlier studies [246, 252] and this work, it is expected that a 
substantial percentage of the un-discovered inhibitors in the putative “non-inhibitor” 
families can be classified as inhibitor despite their family representatives are placed into the 
non-inhibitor training sets.  
 
In conducting large database screening test, 3,653 VEGFR-2 inhibitors reported before 
2012 were used as a training dataset for developing SVM and 92 VEGFR-2 inhibitors 
reported since 2012 [339-345] were used as an independent testing dataset for testing SVM. 
Only 28.57% of the families that contain VEGFR-2 inhibitors reported since 2012 are 
covered in the families that contain at least one VEGFR-2 inhibitor reported before 2012, 
and the representative compounds of these families, none of which happen to be VEGFR-2 
inhibitor, were deliberately placed into the inactive training sets because the inhibitors in 
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these families are not supposed to be known in our study. As shown in earlier studies [246, 
252] and in this work, a substantial percentage of the inhibitors in these misplaced 
inhibitor-containing “non-inhibitor” families were predicted as inhibitors by SVM. 
Moreover, a small percentage of the compounds in these putative non-inhibitor datasets are 
expected to be un-reported and un-discovered inhibitors, their presence in these datasets is 
not expected to significantly affect the estimated false hit rate of SVM.  
 
 
6.3 Results and Discussion 
6.3.1 VEGFR-2 Inhibitor prediction Performance of SVM, kNN and 
PNN evaluated by 5-fold cross validation test 
Table 6-1, 6-2 and 6-3 give the 5-fold cross validation test results of SVM, kNN and PNN 
models in identifying VEGFR-2 inhibitors and non-inhibitors. Figure 6-2 shows 5-fold 
cross validation performance for identifying VEGFR-2 inhibitors across methods with the 
averaged sensitivity together with their respective error bars. Overall, the sensitivity of 
SVM, kNN and PNN is in the range of 93.98%~95.89%, 88.10%~90.00% and 
91.79%~93.01%, the specificity in the range of 99.53%~99.70%, 98.65%~98.72% and 
97.81%~98.01%, and overall accuracy Q in the range of 99.24%~99.45%, 98.10%~98.27% 
and 97.53%~97.69% respectively. The inhibitor accuracies of our SVM are comparable to 
or better than the reported accuracies of 58.3%~67.3% for protein kinase C inhibitors by 
SVM-RBF and CKD methods [192], 83% for Lck inhibitors by SVM method [289], and 
74%~87% for inhibitors of any of the 8 kinases (3 Ser/Thr and 5 Tyr kinases) by SVM, 
ANN, GA/kNN, and RP methods [290]. The non-inhibitor accuracies are comparable to the 
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value of 99.9% for Lck inhibitors [289] and substantially better than the typical values of 
77%~96% of other studies [192, 290]. These are consistent with the result of a study of the 
comparison of SVM with 16 classification methods and 9 regression methods, which has 
shown that SVMs showed mostly good performances both on classification and regression 
tasks but other methods proved to be very competitive [346]. Caution needs to be raised 
about straightforward comparison of these results, which might be misleading because the 
outcome of VS strongly depends on the datasets and molecular descriptors used. Based on 
these rough comparisons, SVM appears to show good prediction capability in identifying 
VEGFR-2 inhibitors at low false-hit rates. Similar prediction accuracies are also found 
from two additional 5-fold cross validation studies conducted by using training-testing sets 
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Table 6-1 Performance of SVM for identifying VEGFR-2 inhibitors and non-inhibitors evaluated by 5-fold 
cross validation study 
Cross 
-Validation 












TN FP SP   
1 2922/731 692 39 94.66% 53585/13397 13335 62 99.54% 99.29% 0.928 
2 2922/731 687 44 93.98% 53585/13397 13334 63 99.53% 99.24% 0.924 
3 2922/731 694 37 94.94% 53586/13396 13356 40 99.70% 99.45% 0.945 
4 2923/730 689 41 94.38% 53586/13396 13349 47 99.65% 99.38% 0.937 
5 2923/730 700 30 95.89% 53586/13396 13343 53 99.60% 99.41% 0.941 
Average    94.77%    99.60% 99.35% 0.935 
Std Dev    0.0072    0.0007 0.0009 0.009 




Table 6-2 Performance of kNN for identifying VEGFR-2 inhibitors and non-inhibitors evaluated by 5-fold 
cross validation study. 
Cross 
-Validation 














TN FP SP   
1 2922/731 644 87 88.10% 53585/13397 13216 181 98.65% 98.10% 0.819 
2 2922/731 644 87 88.10% 53585/13397 13216 181 98.65% 98.10% 0.819 
3 2922/731 646 85 88.37% 53586/13396 13218 178 98.67% 98.14% 0.823 
4 2923/730 657 73 90.00% 53586/13396 13224 172 98.72% 98.27% 0.836 
5 2923/730 646 84 88.49% 53586/13396 13217 179 98.66% 98.14% 0.823 
Average    88.61%    98.67% 98.15% 0.824 
Std Dev    0.0079    0.0003 0.0007 0.007 




Table 6-3 Performance of PNN for identifying VEGFR-2 inhibitors and non-inhibitors evaluated by 5-fold 
cross validation study. 
Cross 
-Validation 














TN FP SP   
1 2922/731 671 60 91.79% 53585/13397 13131 266 98.01% 97.69% 0.799 
2 2922/731 676 55 92.48% 53585/13397 13110 287 97.86% 97.58% 0.794 
3 2922/731 675 56 92.34% 53586/13396 13117 279 97.92% 97.63% 0.797 
4 2923/730 675 55 92.47% 53586/13396 13102 294 97.81% 97.53% 0.791 
5 2923/730 679 51 93.01% 53586/13396 13110 286 97.87% 97.61% 0.797 
Average    92.42%    97.89% 97.61% 0.796 
Std Dev    0.0044    0.0008 0.0006 0.003 






Figure 6-2 Performance for identifying VEGFR-2 inhibitors evaluated by 5-fold cross validation study 
across methods. This figure is illustrating the 5-fold cross validation studies of VEGFR-2 inhibitors 
across methods with the averaged sensitivity together with their respective error bars. 
 
 
6.3.2 Virtual screening performance of SVM in searching 
VEGFR-2 inhibitors from large compound libraries  
A SVM in searching VEGFR-2 inhibitors from large libraries was developed by using 
VEGFR-2 inhibitors reported before 2012. The VS performance of this SVM in 
identifying VEGFR-2 inhibitors reported since 2012 and in searching MDDR and 
PubChem databases is summarised in Table 6-4. The yield in searching VEGFR-2 
inhibitors reported since 2012 is 85.87%, which is comparable to the reported 
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50%~94% yields of various VS tools [291]. Strictly speaking, direct comparison of 
the reported performances of these VS tools is inappropriate because of the 
differences in the type, composition and diversity of compounds screened, and in the 
molecular descriptors, VS tools and their parameters used. The comparison cannot go 
beyond the statistics of accuracies as the reports are not detailed enough to address 
questions of whether all methods detect the same hit.  
 
Table 6-4 Virtual screening performance of support vector machines for identifying VEGFR-2 
inhibitors from large compound libraries 
Inhibitors in Training 
Dataset 
No of Inhibitors 3653 
No of Chemical Families Covered by Inhibitors 845 
Inhibitors in Testing 
Dataset 
No of Inhibitors 92 
No of Chemical Families Covered by Inhibitors 35 
Percent of Inhibitors in Chemical Families Covered by 





No and Percent of Identified True Inhibitors Outside 
Training Chemical Families 
31 (39.24%) 






No and Percent of the 168K MDDR Compounds Identified 
as Inhibitors 
2,717 (1.62%) 
No and Percent of the 13,872 MDDR Compounds Similar 
to the Known Inhibitors Identified as Inhibitors 
1,714 
(12.36%) 
Virtual-hit rates and false-hit rates of SVM in screening compounds that resemble the 
structural and physicochemical properties of the VEGFR-2 inhibitors were evaluated 
by using 13,872 MDDR compounds similar to a VEGFR-2 inhibitor in the training 
dataset. Similarity was defined by Tanimoto similarity coefficient ≥0.9 between a 
MDDR compound and its closest dual-inhibitor [252]. This stricter similarity metric 
was used for conducting a stricter test of our SVM model. SVM identified 1,714 
virtual-hits from these 13,872 MDDR similarity compounds (virtual-hit rate 12.36%), 
which suggests that SVM has some level of capability in distinguishing VEGFR-2 
inhibitors from similarity non-inhibitors. Significantly lower virtual-hit rates and thus 
false-hit rates were found in screening large libraries of 168K MDDR and 13.56M 
PubChem compounds. The numbers of virtual-hits and virtual-hit rates in screening 
168K MDDR compounds are 2,717 and 1.62% respectively. The numbers of 
virtual-hits and virtual-hit rates in screening 13.56M PubChem compounds are 31,624 




Many of the 2,717 MDDR virtual-hits belong to the classes of antineoplastic (45.3%), 
tyrosine-specific protein kinase inhibitor (12.7%), signal transduction inhibitor 
(12.7%), antiarthritic (11.0%), and antiangiogenic (9.3%), antihypertensive (5.1%), 
antiallergic/antiasthmatic (4.3%), and antidepressant (3.4%) (Table 6-5, details in 
next section). As some of these virtual-hits may be true VEGFR inhibitors, the 
false-hit rate of our SVM is at most equal to and likely less than the virtual-hit rate. 
Hence the false-hit rate is ≤12.36% in screening 13,872 MDDR similarity 
compounds, ≤1.62% in screening 168K MDDR compounds, and ≤0.23% in screening 
13.56M PubChem compounds, which are comparable and in some cases better than 
the reported false-hit rates of 0.0054%~8.3% of SVM [246, 252], 0.08%~3% of 
structure-based methods, 0.1%~5% by other machine learning methods, 0.16%~8.2% 
by clustering methods, and 1.15%~26% by pharmacophore models [291]. 
 
6.3.3 Experimental test of a SVM identified virtual-hit 
Three virtual hits of the same novel scaffold from in-house libraries not found in the 
known the VEGFR-2 inhibitor were evaluated for inhibitory activity against 
VEGFR-2. VEGFR-2 kinase was incubated with substrates, compounds and ATP in a 
final buffer of 25mM HEPES (pH 7.4), 10mM MgCl2, 0.01% Triton X-100, 
100µg/mL BSA, 2.5mM DTT in 384-well plate with the total volume of 10µl. The 
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assay plate was incubated at 30℃ for 1h and stopped with the addition of equal 
volume of kinase glo plus reagent. The luminescence was read at envision. The signal 
was correlated with the amount of ATP present in the reaction and was inversely 
correlated with the kinase activity. One of three virtual hits shown in Figure 6-3 was 





Figure 6-3 The structure of a SVM virtual hit tested to show moderate VEGFR-2 inhibitory activity. 
 
6.3.4 Evaluation of SVM identified MDDR virtual-hits 
SVM identified MDDR virtual-hits were evaluated based on the known biological or 
therapeutic target classes specified in MDDR. Table 6-5 gives the MDDR classes that 
contain higher percentage (≥3%) of SVM virtual-hits and the percentage values. We 
found that 1,230 or 45.3% of the 2,717 virtual-hits belong to the antineoplastic class, 
which represent 5.7% of the 21,557 MDDR compounds in the class. In particular, 346 
or 12.7% of the virtual-hits belong to the tyrosine-specific protein kinase inhibitor 
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class, which represent 29.3% of the 1,181 MDDR compounds in the class. Moreover, 
12.7% and 9.4% of the virtual-hits belong to the signal transduction inhibitor and 
antiangiogenic classes, representing 16.9% and 15.7% of the 2,037 and 1,629 
members in the two classes respectively. Therefore, many of the SVM virtual-hits are 
antineoplastic compounds that inhibit tyrosine kinases and possibly other kinases 
involved in signal transduction, angiogenesis and other cancer-related pathways. 
Some of these SVM selected kinase inhibitors might have VEGFR inhibitory 
activities, and others were expectedly selected due to false selection of inhibitors of 
other kinases (at ≤1.62%~12.36% false-hit rates).  
 
Table 6-5 MDDR classes that contain higher percentage (≥3%) of SVM virtual -hits and the percentage 
values. Virtual-hits are identified by SVMs in screening 168K MDDR compounds for VEGFR-2 
inhibitors. The total number of SVM identified virtual hits is 2,717. 
 
MDDR Classes that Contain Higher Percentage 
(>3%) of Virtual Hits  
No and Percentage of 
Virtual Hits in Class  
Percentage of Class 
Members Selected as 
Virtual Hits 
Antineoplastic 1230 (45.3%) 5.7% 
Tyrosine-Specific Protein Kinase Inhibitor 346 (12.7%) 29.3% 
Signal Transduction Inhibitor 345 (12.7%) 16.9% 
Antiarthritic 300 (11.0%) 2.6% 
 138 
 
Antiangiogenic 256 (9.3%) 15.7% 
Antihypertensive 139 (5.1%) 1.3% 
Antiallergic/Antiasthmatic 118 (4.3%) 1.1% 
Antidepressant 93 (3.4%) 1.5% 
 
Substantial percentages of the SVM virtual-hits belong to the antiarthritic (11.0%), 
antihypertensive (5.1%), and antiallergic/antiasthmatic (4.3%) therapeutic classes. 
Some VEGFR inhibitors have been reported to show respective therapeutic effects. 
VEGF has been related to such autoimmune diseases as systemic lupus 
erythematosus, rheumatoid arthritis, and multiple sclerosis [295]. Both VEGFR-1 and 
VEGFR-2 are expressed in human osteoarthritic cartilage [347]. VEGFR-2 and 
VEGFR-3 are present in most of the sublining blood vessels in arthritic synovium 
[348]. A VEGFR-2 inhibitor, PTK787/ZK222584, has been reported to cause 
significant anti-arthritic effects in models of rheumatoid arthritis via anti-angiogenic 
actions [349]. Hypertension is characterized by the development of a hyperdynamic 
circulation which can be markedly inhibited by EGFR-2 inhibitor (e.g. SU5416) 
blockade of the VEGF signaling pathway, leading to the consideration of modulation 
of angiogenesis for the treatment of hypertension [350]. VEGFR-2 and VEGFR-1 
have been shown to be involved in the pathogenesis of the contact hypersensitivity 
reaction, and both the induction and elicitation phases of contact hypersensitivity can 
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be inhibited by VEGFR inhibitor PTK787/ZK 222584 [351]. Therefore, some of the 
SVM virtual-hits in the antiarthritic, antihypertensive, and antiallergic/antiasthmatic 
classes may be VEGFR inhibitors capable of producing the respective therapeutic 
effects.  
 
Moreover, 93 (3.4%) of the SVM virtual hits are in the antidepressant class. It has 
been reported that depressive episodes in the context of borderline personality 
disorder may be accompanied by increased serum concentrations of VEGF and FGF-2 
[352]. VEGF has been implicated in neuronal survival, neuroprotection, regeneration, 
growth, differentiation, and axonal outgrowth, which is involved in the 
pathophysiology of major depressive disorder and the higher expression levels of 
VEGF in the peripheral leukocytes are associated with the depressive state [353]. 
Therefore, there is a possibility that inhibition of VEGFR signalling may have some 
level of antidepressant effect or act as enhancer of other antidepressant agents [354], 
and some of the SVM virtual hits in the antidepressant class may be possible VEGFR 




6.3.5 Comparison of virtual screening performance of SVM with 
tanimoto-based similarity searching method 
To evaluate whether the performance of SVM is due to the SVM classification 
models or to the molecular descriptors used, SVM results were compared with those 
of three other VS methods based on the same molecular descriptors, training dataset 
of VEGFR-2 inhibitors reported before 2012, and the testing dataset of VEGFR-2 
inhibitors reported since 2012 and 168K MDDR compounds. The three other VS 
methods include two similarity-based methods, Tanimoto-based similarity searching 
and kNN methods, and an alternative machine learning method PNN. As shown in 
Table 6-6, the yield and maximum possible false-hit rate of the Tanimoto-based 
similarity searching, kNN and PNN methods are 73.91% and 8.26%, 54.35% and 
2.48% , and 54.35%  and 3.30% respectively. 
 
Compared to these results, the yield of SVM is significantly improved and the 
false-hit rate of SVM is substantially reduced. This suggests that SVM performance is 
due primarily to the SVM classification models rather than the molecular descriptors 
used, and SVM is capable of achieving comparable yield at substantially reduced 




Table 6-6 Comparison of virtual screening performance of SVM with those of other methods 
 
Method Inhibitors in Training Set Inhibitors in Testing Set Virtual Screening Performance  





















Yield  No and Percent 





No and Percent of 




No and Percent of 
the 13,872MDDR 
Compounds Similar 
to the Known 
Inhibitors Identified 
as Virtual Inhibitors 
Support Vector 
Machines 
3653 845 92 35 56.52% 
85.87% 31 (39.24%) 2,717 (1.62%) 1,714 (12.36%) 
Tanimoto 
Similarity 
73.91% 32 (47.06%) 13,872 (8.26%) 13,872 (100%) 
K Nearest 
Neighbour 
54.35% 12 (24.00%) 4164 (2.48%) 2,689 (19.38%) 
Probabilistic 
Neural Network 




6.3.6 Does SVM select VEGFR inhibitors or membership of 
compound families? 
To further evaluate whether SVM identifies VEGFR-2 inhibitors rather than 
membership of certain compound families, Compound family distribution of the 
identified VEGFR-2 inhibitors and non-inhibitors were analyzed. A total of 39.24% 
of the identified VEGFR-2 inhibitors belong to the families that contain no known 
VEGFR-2 inhibitors. For those families that contain at least one known inhibitor, 
>70% of the compounds (>90% in majority cases) in each of these families were 
predicted as non-inhibitor by SVM. These results suggest that SVM identifies 
VEGFR-2 inhibitors rather than membership to certain compound families. Some of 
the identified inhibitors not in the family of known inhibitors may serve as potential 
“novel” VEGFR-2 inhibitors. Therefore, as in the case shown by earlier studies [319], 
SVM has certain capacity for identifying novel active compounds from sparse as well 
as regular-sized active datasets. 
 
6.4 Concluding remarks 
By using training dataset of more diverse spectrum of inactive compounds as well as 
substantial number of literature-reported VEGFR-2 inhibitors, SVM shows substantial 
capability in identifying VEGFR-2 inhibitors at comparable yield and in many cases 
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substantially lower false-hit rate than those of typical VS tools reported in the 
literatures. It is capable of searching large compound libraries at sizes comparable to 
the 13.56M PubChem and 168K MDDR compounds at low false-hit rates. The 
performance of SVM is significantly better than that of Tanimoto-based similarity 
search method based on the same datasets and molecular descriptors, suggesting that 
the VS performance of SVM is primarily due to SVM classification models rather 
than the molecular descriptors used. Because of their high computing speed and 
generalization capability for covering highly diverse spectrum compounds, SVM can 
be potentially explored to develop useful VS tools to complement other VS methods 
or to be used as part of integrated VS tools in facilitating the discovery of VEGFR 




Chapter 7 Concluding remarks  
7.1 Major findings and merits 
7.1.1 Merits of the development of MicrobPad MD: microbial 
pathogen diagnostic methods database 
In this work, we developed the microbial pathogen diagnostic methods database 
MicrobPad to provide comprehensive information about the molecular diagnostic 
techniques, targets, primers/probes, detection procedures and conditions, and tested 
diagnostic accuracies and limit of diagnosis for 314 bacterial, fungal and viral species 
from 61 genera. While available, additional information such as pathogen strains and 
hosts, tissue distribution or habitats, cultivation methods, biochemical characteristics, 
virulence factors, morphology, diseases, symptoms, treatment and prevention methods 
are provided. Our Database covers 242 gene targets, 700 primers/ probes, 340 
virulence factors, and 261 diseases. Cross-links to the NCBI genome and 
SwissProt/UniProt databases are provided. This work can facilitate accurate, sensitive 
and low-cost diagnosis of medical pathogens and also boost the development of 




7.1.2 Merits of the updates of TTD in facilitating multi-target drug 
discovery 
TTD providing pharmaceutical information on therapeutic target is a reliable 
knowledge hub for established therapeutic target since it is developed. However, the 
profile of drugs under clinical developing keeps changing in the past decade, and 
many new drugs have been approved for acting on some new targets. Moreover, many 
drugs in previous TTD did not indicate their primary target, and there is no 
information of drugs in clinical trial provided. TTD 2010 update takes these 
challenges and tries to offer a most comprehensive map of drug targets for the modern 
pharmaceutical era. In this updated version, TTD significantly expanding target data 
to 348 successful, 292 clinical trial, and 1,254 research targets, and 560 diseases, and 
added drug data for 1,514 approved, 1,212 clinical trial and 2,302 experimental drugs 
linked to their primary targets (3382 small molecule and 649 antisense drugs with 
available structure and sequence). Other features which add additional credits to TTD 
2010 include: (1) collection of information of antisense, aptamer and siRNA based 
drugs; (2) allowance of customized target search by disease indications, target 
biochemical classes, drug mode of actions, drug therapeutic classes, and so on; (3) 
allowance of target search by BLAST; (4) allowance of drug search by tanimoto 
similarity; and (5) user friendly interface and full data download. Comprehensive data 
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integrated, primary targets identified, detail clinical trial stage for both drugs and 
targets labeled, and functional features added guarantee this version of TTD a reliable, 
informative, useful, multifunctional and convenient source of drug target information. 
7.1.3 Merits of virtual screening model for Src inhibitors 
We evaluated support vector machines (SVM) as virtual screening tools for searching 
Src inhibitors from large compound libraries. SVM trained and tested by 1,703 
inhibitors and 63,318 putative non-inhibitors correctly identified 93.53%~ 95.01% 
inhibitors and 99.81%~ 99.90% non-inhibitors in 5-fold cross validation studies. 
SVM trained by 1,703 inhibitors reported before 2011 and 63,318 putative 
non-inhibitors correctly identified 70.45% of the 44 inhibitors reported since 2011, 
and predicted as inhibitors 44,843 (0.33%) of 13.56M PubChem, 1,496 (0.89%) of 
168K MDDR, and 719 (7.73%) of 9,305 MDDR compounds similar to the known 
inhibitors. We also compared SVM models with other machine learning methods 
including kNN, PNN and Tanimoto similarity searching method with the same 
dataset. SVM showed comparable yield and reduced false hit rates in searching large 
compound libraries compared to the similarity-based and other machine-learning VS 
methods developed from the same set of training compounds and molecular 
descriptors. We tested three virtual hits of the same novel scaffold from in-house 
chemical libraries not reported as Src inhibitor, one of which showed moderate 
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activity. SVM may be potentially explored for searching Src inhibitors from large 
compound libraries at low false-hit rates. 
 
7.1.4 Merits of virtual screening model for VEGFR-2 inhibitors 
Approach for identification of VEGFR-2 inhibitors from large compound libraries by 
SVM virtual screening model was constructed. SVM trained and tested by 3,653 
inhibitors and 66,982 putative non-inhibitors correctly identified 93.98%~95.89% 
inhibitors and 99.53%~99.70% non-inhibitors in 5-fold cross validation studies. SVM 
trained by 3,653 inhibitors reported before 2012 and 66,982 putative non-inhibitors 
correctly identified 85.87% of the 92 inhibitors reported since 2012, and predicted as 
inhibitors 31,624 (0.23%) of 13.56M PubChem, 2,717 (1.62%) of 168K MDDR, and 
1,714 (12.36%) of 13,872 MDDR compounds similar to the known inhibitors. Based 
on this model, one of three virtual hits was experimental found to inhibit VEGFR-2 at 
a moderate rate of 4.54% at 20µM. In summary, SVM showed substantial capability 
in searching VEGFR-2 inhibitors from large compound libraries at low false-hit rates. 
 
7.2 Limitations and suggestions for future studies 
MicrobPad MD consists of data of medical pathogens of bacterial, fungal, and viral 
species. There are innumerable medical pathogens in the nature and more and more 
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are recognized. The number and the diversity of species need to be expanded. New 
techniques develop quickly, more effective pipeline are needed to process increasing 
data quickly. More functions are also necessary to added such as portal of data 
transfer for further applications and utilization of controlled vocabulary space for 
large scale of data. 
 
Current TTD provides information of targets and drugs on clinical trial phase o which 
is one of most crucial characteristic. However, the clinical trial status keeps changing 
for our modern pharmacology is a dynamically moving process, it is difficult to 
update it manually. A solution to this may be to integrate automatic information 
system which helps TTD to search latest data update from reliable sources. Other 
function such as similarly, docking and QSAR model can be implemented. 
 
The compound descriptors of current SVM approach were calculated using our 
MODEL software. It provides more than 500 diverse types descriptors. However, 
these still do not cover all the important descriptors. As shown in the study of acute 
toxicity, some more important descriptors shall be included and evaluated. 
 
The generation of putative negatives was used for the machine learning methods 
application. This approach requires a classification of the chemical space which has 
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always been a difficult task in chemoinoformatics. The classification of the chemical 
space needs a clustering method, a distance matrix selection and descriptors. K-means 
clustering method was used in this work. It is not the best clustering method but is 
suitable and computable for large chemical spaces. In future studies, more advanced 
clustering algorithm can be developed for improving the accuracy of chemical space 
clustering. Additionally, the selection of correlation coefficients and other chemical 
descriptors such as fingerprint can also help the improvement. Another possible 
drawback associated with the putative negatives generation approach is the possible 
inclusion of some undiscovered active compounds in the “inactive” class. This may 
hinder the identification of novel active compounds by machine learning methods. 
However, such an adverse effect is expected to be relatively small for many biological 
target classes.  
 
There is no conclusive answer to which VS approach is the best. Both ligand based 
and structural based methods have their own advantages and drawbacks. Therefore, 
the choice of one or another depends on the specific case faced by the medicinal 
chemist. In terms of performance, ligand based methods have the advantage of better 
enrichment factors and higher speed serving and they are more efficient in removing 
non active compounds; structure based methods provide a more direct view of the 
interactions between the ligand and molecular target and it has an advantage for the 
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detecting of novel structures. The VS approaches aims to firstly include less costly 
approaches, usually ligand based VS, at the first stage and apply the most demanding 
methods, such as docking, for the last stage when the original large compound library 
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